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Executive summary
Rapid demographic, sociocultural, and economic 
transitions are driving increases in the risk and prevalence 
of diabetes and other non-communicable diseases 
(NCDs) in sub-Saharan Africa. The impacts of these 
transitions and their health and economic consequences 
are evident. Whereas, in 1990, the leading causes of death 
in sub-Saharan Africa were HIV/AIDS, lower respiratory 
infections, diarrhoeal diseases, malaria, and vaccine-
preventable diseases in children, in more recent years, 
cardiovascular diseases and their risk factors are replacing 
infectious diseases as the leading causes of death in this 
region, and rates of increase of cardiovascular risk factors 
are predicted to be greater in sub-Saharan Africa than in 
other parts of the world. Thus, sub-Saharan Africa—
which contains a high proportion of the world’s least 
developed countries—will face the multifaceted challenge 
of dealing with a high burden of infectious diseases and 
diseases of poverty, while also addressing the increasing 
burden of cardiovascular disease and its risk factors. At 
present, many of the health systems in sub-Saharan 
Africa struggle to cope with infectious diseases. Meeting 
the goals of the UN high-level meeting on NCDs (to 
reduce premature mortality from NCDs by 25% by 2025) 
and Sustainable Development Goals (SDGs; to reduce 
premature mortality from NCDs by a third by 2030) 
requires a coordinated approach within countries, which 
starts with a firm consideration of disease burden, needs, 
and priorities.
Diabetes is an exemplar risk factor of cardiovascular 
disease in that its prevalence tracks the transitions that 
lead to the precursors of cardiovascular disease—namely 
obesity and overweight. The prevalence of diabetes is 
increasing rapidly in sub-Saharan Africa.1 If left 
untreated, diabetes leads to a plethora of complications, 
both microvascular and macrovascular, that affect 
multiple physiological systems. Additionally, diabetes is 
closely associated with other cardiovascular risk factors, 
including hypertension and hypercholesterolaemia, 
which interact to exacerbate the risk of adverse outcomes. 
Thus, diabetes requires an interconnected, broad-based 
health system for its effective management. Improving 
the processes of care for people with diabetes should lead 
to improvement of health systems for many other 
conditions. If left unchecked, however, the adverse 
outcomes of diabetes and other cardiovascular risk 
factors could overwhelm health systems in sub-Saharan 
Africa and leave many of those affected with substantial 
morbidity and mortality. The interaction of diabetes with 
infectious diseases further increases the burden of 
illness on resource-constrained health systems. 
The Lancet Diabetes & Endocrinology Commission on 
Diabetes in sub-Saharan Africa was formed to ascertain 
the current burden of diabetes and its risk factors and 
outcomes in the region, to assess challenges faced by 
health systems in dealing with this burden, and to 
suggest potential solutions. We present the key messages 
of the Commission below and also suggest operational 
targets (panel 1) to help countries at all stages of 
development to transition to a state whereby the UN and 
SDG targets on NCDs can be achieved, if not surpassed.
Key message 1: the true burden of diabetes, other 
cardiovascular risk factors, and macrovascular and 
microvascular complications in sub-Saharan Africa is 
unknown
Estimates from those countries in which high-quality 
data are available suggest that the increase in the 
prevalence of diabetes, other cardiovascular risk factors, 
and adverse outcomes is large and is expected to further 
increase. However, most countries do not have data or 
data collection systems that are sufficiently reliable to 
enable mounting of a commensurate health-system 
response. To plan such a response requires high-quality, 
population-representative data on both current burdens 
and associated demographic factors and that systems for 
longitudinal data collection be put in place. It is also 
imperative to ascertain which tests and cutoffs for 
hyperglycaemia are most appropriate for use in defining 
diabetes in populations in sub-Saharan Africa to prevent 
overtreatment or undertreatment.
Knowledge about the burden of type 1 diabetes is 
particularly important given that this condition is fatal in 
the absence of relatively inexpensive treatment.
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Key message 2: diabetes and its consequences are costly 
to patients and economies
We estimate that, in 2015, the overall cost of diabetes in 
sub-Saharan Africa was US$19·45 billion or 1·2% of 
cumulative gross domestic product (GDP). Around 
$10·81 billion (55·6%) of this cost arose from direct costs, 
which included expenditure on diabetes treatment (eg, 
medication, hospital stays, and treatment of 
complications), with out-of-pocket expenditure likely to 
exceed 50% of the overall health expenditure in many 
countries. We estimate that the total cost will increase to 
between $35·33 billion (1·1% of GDP) and $59·32 billion 
(1·8% of GDP) by 2030. Putting in place systems to 
prevent, detect, and manage hyperglycaemia and its 
consequences is therefore warranted from a health 
economics perspective.
Key message 3: health systems in countries in 
sub-Saharan Africa are unable to cope with the current 
burden of diabetes and its complications
By use of information from WHO Service Availability 
Readiness Assessment surveys and World Bank Service 
Delivery Indicator surveys and the local knowledge of 
Commissioners, we found inadequacies at all levels of 
the health system required to provide adequate 
management for diabetes and its associated risk factors 
and sequelae. We found inadequate availability of 
simple equipment for diagnosis and monitoring, a lack 
of sufficiently knowledgable health-care providers, 
insufficient availability of treatments, a dearth of locally 
appropriate guidelines, and few disease registries. 
These inadequacies result in a substantial dropoff of 
patients along the diabetes care cascade, with many 
patients going undiagnosed and with those who are 
diagnosed not receiving the advice and drugs they need. 
We also noted scarce facilities to manage the 
microvascular and macro vascular complications of 
diabetes. Additionally, despite calls for adding the care 
of diabetes and other cardiovascular risk factors onto 
existing infectious disease programmes (such as those 
for HIV), we found little evidence that such combined 
programmes are successful at improving outcomes.
Key message 4: scarce health-care resources should be 
focused on the management of diabetes and other risk 
factors to prevent complications
The management of diabetes and its risk factors is 
reasonably simple and inexpensive. Treating compli-
cations, however, is costly, requiring providers with a 
high level of skill and specialised equipment. 
Prevention of complications is therefore crucial. To 
allow effective prevention of complications, de-
centralisation of care—from experts who work in 
hospitals to community health workers and other non-
clinical providers who work in the primary care system 
and deliver home-based screening and care—needs to 
be accelerated. Simple and effective information 
technology solutions should be used to enable more 
locally delivered care. An additional consideration is 
whether it is more beneficial to treat each risk factor 
associated with diabetes to predefined targets, or to 
consider risk factors collectively and aim to reduce 
overall risk. For both the prevention of macrovascular 
and microvascular risk factors, our analyses suggest it 
will be more effective and cost-effective to consider risk 
factors as a whole, and use benefit-based tailored 
treatment, rather than to treat each individual 
cardiovascular risk factor to a target.
Panel 1: Priorities and targets for diabetes care to 2030
When health resources are severely limited, difficult choices must often be made in the 
face of competing priorities. Our review of the challenges involved makes it clear that 
models of diabetes care for use in high-income countries are neither appropriate nor 
affordable in low-income or middle-income countries. We advocate the pursuit of a 
utilitarian approach to the provision of diabetes care in most sub-Saharan African 
settings, involving widely available inexpensive treatments for prevention of 
complications alongside strong public health measures to prevent increases in the 
prevalence of obesity and diabetes. Investment in preventing the consequences of 
diabetes will prevent the necessity of investing in wider-scale availability of expensive 
treatments to manage diabetes complications. Rigorous health-systems research and 
implementation science2 to accompany the introduction of new treatments or 
management strategies are key to ensuring that solutions are both fitting to a local 
environment and that results obtained can be of use to other countries. Funding for this 
type of research is urgently required.
We therefore propose a hierarchy-of-needs model of care on the basis of strategies 
known to work in other settings. This hierarchy is based on the Commissioners’ 
experience in both clinical care and health-system improvement and our review of the 
literature during the process of this Commission. The principles of this hierarchy are 
straightforward: each intervention should be evidence-based, effective, accessible, 
integrated, and affordable. Of key importance, the Commission calls for services for 
provision of care and diagnostics for diabetes, its risk factors, and its complications to be 
fully integrated to minimise the indirect costs to the patient of having to attend multiple 
clinic appointments.
The prerequisites for introduction of treatment modalities or therapies are education and 
structure. The aims of education are achieved at personal, community, and 
health-care-provider levels. At a personal level, the aim is to make the patient an active, 
informed partner in their own therapy rather than a passive recipient. At the community 
level, the aim is to increase understanding and awareness of diabetes and eliminate 
prejudice. Education of medical personnel is needed to raise awareness of the disease and 
the simplicity of its treatment, and also to counterbalance marketing and medical 
education campaigns by the pharmaceutical industry, which are typically slanted towards 
use of more expensive, patented forms of treatment. An appropriate structure for 
health-care delivery, which is embedded in the health system, is equally essential.
We have considered necessary care needs in terms of the level of service-provision 
development in countries. We progress from care that we consider to be essential (which we 
refer to as level one care) and recommend should be available in 100% of countries by 2020; 
to level two care, which we consider should be the next step when level one care is achieved 
and should be available in 75% of countries by 2020 and in 100% of countries by 2025; and 
then to level three care, which should be considered once other targets have been achieved. 
We recommend that level three care should be present in 50% of countries by 2020, 75% of 
countries by 2025, and 100% of countries by 2030 (table 1).
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Key message 5: more evidence is needed about the 
benefits and risks (to individuals and health systems) of 
screening before programmes are rolled out across 
sub-Saharan Africa
The benefits of screening, especially in people who are 
deemed to be at high risk, seem obvious: earlier detection 
and management of diabetes and its risk factors and 
prevention of costly complications. However, as of yet, 
there is little evidence—even from high-income countries, 
where studies have been done—that screening 
programmes are effective at reducing adverse outcomes. 
Additionally, the thresholds for diagnosing diabetes (ie, the 
level of glycaemia that is associated with the risk of adverse 
outcomes in the long term) and the best test to use are not 
defined for populations in sub-Saharan Africa. Hence, any 
screening programme that is started should only be done 
Level one Level two Level three
Target 100% availability or uptake by 2020 75% availability or uptake by 2020; 100% availability or 
uptake by 2025
50% availability or uptake by 2020; 75% availability or 
uptake by 2025; 100% availability or uptake by 2030
Medications 
and equipment
Availability of treatments for hyperglycaemia 
(metformin, sulfonylureas, and short-acting and 
intermediate-acting human insulin) at health-care 
facilities at all levels (including community facilities and 
pharmacies) 
Availability of essential medicines for hypertension at all 
health facilities (including community facilities and 
pharmacies) 
Availability of angiotensin-converting enzyme inhibitors 
to treat diabetic nephropathy and prevent microvascular 
disease at all health-care facilities (including community 
facilities and pharmacies) 
Availability of off-patent medicines to treat 
hyperlipidaemia at all health-care facilities 
Availability of blood glucose and ketone sticks at all health 
facilities (including community health facilities) 
Availability of working sphygmomanometers of 
appropriate cuff size at all health facilities 
(including community health facilities)
Availability of essential medicines for secondary 
prevention of cardiovascular disease at all health-care 
facilities (including community facilities and 
pharmacies) 
Access to home urine glucose sticks for patients to 
assess glycosuria at least three times per week 
Availability of affordable and sustainable technologies 
for self-monitoring of blood glucose in those people 
with diabetes using insulin 
Availability of affordable or portable digital photography 
equipment for taking and transmitting retinal images 
for remote interpretation 
Availability of affordable or portable equipment for 
retinal image acquisition, image transfer, and image 
grading 
Provision of laser equipment for treatment of diabetic 
retinopathy
Availability of affordable and sustainable self-
monitoring of blood glucose equipment for all patients 
with diabetes, and availability of glucose strips for 
testing at least three times per day on 3 days per week 
Therapeutic options for erectile dysfunction 
Orthotics for people with foot deformities to prevent 
ulceration 
Availability of intravitreal anti-VEGF drugs to treat 
diabetic retinopathy
Service delivery Availability of services to provide education and 
counselling for patients with diabetes or gestational 
diabetes at all health-care facilities 
Availability of screening for gestational diabetes with 
2013 WHO criteria3 for high-risk women attending 
antenatal services at all health-care facilities 
Availability of regular (3 monthly) follow-up for diabetes 
and associated conditions via community health 
workers or primary care facilities 
Availability of services to deliver regular supplies of 
medicines within patients’ local areas 
Clearly delineated referral pathways between 
community, secondary, and specialised or tertiary care 
centres
Availability of laboratory tests for fasting blood glucose, 
HbA1C, and renal function at all secondary and tertiary 
referral centres 
Availability of services to screen for diabetic retinopathy, 
integrated into general services for diabetes care 
Access to tertiary care facilities for treatment of cataracts 
and retinopathy 
Availability of community support groups 
Availability of annual review at a specialist diabetes clinic 
(with facilities for annual HbA1C measurement, screening 
for complications, assessment of proteinuria with urine 
strips, measurement of serum creatinine, retinal 
photography for people at high risk of retinopathy, and 
monofilament or tuning fork testing for peripheral 
neuropathy) for all patients with diabetes
Access to secondary or tertiary care facilities for cataract 
surgery and treatment of diabetic retinopathy with laser 
and intravitreal anti-VEGF drugs 
Access to tertiary care facilities for vitreoretinal surgery 
to treat advanced diabetic retinopathy 
Wide-scale access to dialysis and renal transplantation, 
vascular surgery for peripheral vascular disease, and 
percutaneous coronary intervention and coronary artery 
bypass grafting at tertiary care facilities 
Rehabilitation programmes and prostheses for people 
after a stroke or amputation
Information At the diabetes clinic level, ensure availability of simple, 
future-proof diabetes registries to allow documentation of 
diabetes control, medications, and complications, and 
triggering of recall 
Availability of information technology to allow remote 
interpretation of digital retinal photos taken in clinics in 
which no expertise in interpretation is available 
Availability of basic diabetes education, including 
information about prevention and detection of 
complications, that is culturally appropriate, provided in 
a local language, and understandable to patients and 
their relatives 
Widespread availability of information about and 
campaigns to promote a healthy lifestyle that is tailored 
to the local population, culturally appropriate, and 
delivered through media platforms that are widely used 
by the local population 
Availability of a basic cardiovascular risk calculator at 
each primary health-care facility
Availability of electronic links between specialist 
diabetes clinics and primary care providers, allowing 
updates on test results, prescription modification, and 
follow-up and referral information 
Availability of a cloud-based storage system for storage 
of and access to electronic diabetes records by primary 
and secondary providers 
Availability of a mobile phone alert system to 
communicate results and changes to treatments to 
patients and to alert patients to follow-up appointments 
Availability of equipment allowing yearly training 
updates for primary health-care workers and others 
providing diabetes care, to be delivered by distance 
learning
Fully integrated, cloud-based patient information 
systems for storing diabetes-relevant information along 
with all other key records of diagnoses and treatment
(Table 1 continues on next page)
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as part of a rigorous longitudinal outcomes study that also 
compares different tests for diagnosis of hyperglycaemia.
Introduction
Sub-Saharan Africa is experiencing a rapid increase in 
the prevalence of non-communicable diseases (NCDs). 
Although, in 2015, Africa was the only continent in the 
world where morbidity and mortality from infectious 
diseases still surpassed that from NCDs, this balance will 
soon change as the region experiences the full impact of 
the increase in NCDs.6
Rapid demographic (growing and ageing population), 
sociocultural (lifestyle changes and eating habits), and 
economic (higher income, urbanisation, changing food 
availability, and evolving lifestyle and work practices) 
transitions7,8 are driving increases in the risk factors and 
Level one Level two Level three
(Continued from previous page)
Workforce Training (with ongoing regular support and mentoring) 
of enough community health-care workers (appropriate 
to current and projected burden) in each region to aid 
case finding and provide adherence support and 
preventive care and information 
Training of health-care workers who provide antenatal 
care to recognise women at high risk of gestational 
diabetes and refer them to antenatal services offering 
screening and treatment 
Ensure all primary care providers are trained to recognise 
and treat hyperglycaemia 
Ensure all primary care providers are trained to screen for 
and treat associated cardiovascular risk factors in 
patients with diabetes and recognise when to refer a 
patient for more specialised care 
Provision of training on recognition and referral of 
diabetic retinopathy cases to the existing eye-care 
workforce
Trained diabetes educators in each district to support 
community health workers and people with diabetes 
Training for all health-care providers to recognise the 
symptoms of diabetes and its complications, as well as the 
means of diagnosis 
Ensure availability of one paediatric and one adult 
endocrinologist at each tertiary care centre in each 
country 
Provide training on diabetes to traditional healers to 
allow them to recognise the symptoms and refer 
potential sufferers to medical care 
Ensure availability of appropriately trained retinal 
photographers and retinal image graders 
Ensure availability of one or more ophthalmologist 
trained to deliver treatment for diabetic retinopathy in 
each tertiary care centre in each country
Specialist diabetes workforce expanded to enable one 
annual visit for each patient with a fully trained 
diabetologist 
Availability of multidisciplinary teams for the 
management of hyperglycaemia in pregnancy
Financing Ensure all necessary care for diabetes and associated 
cardiovascular risk factors is made freely available to 
those living below the World Bank 20154 defined poverty 
line of US$1·90 per day
Ensure all essential care for diabetes and associated 
cardiovascular risk factors (including access to screening, 
regular follow-up [including blood tests], access to 
medicines for primary and secondary prevention, 
follow-up by a specialist once per year, and detection of 
microvascular complications) is covered by universal 
health coverage schemes such that no patient has to pay 
direct costs of care out of pocket
Ensure availability of detection and treatment facilities 
for macrovascular and microvascular complications of 
diabetes, with no patient suffering catastrophic 
expenditure for accessing care
Knowledge Ascertain most appropriate method (in terms of 
predicting future complications) for diagnosing diabetes 
in sub-Saharan Africa 
Ascertain most appropriate method (in terms of ability 
to predict maternal and neonatal complications) of 
diagnosing gestational diabetes 
Ascertain most appropriate method for retinal image 
acquisition, image grading, and targeted case detection 
in low-resource environments
Obtain reliable in-country estimates (for example, with 
the STEPwise approach to surveillance method5) from 
adequately sized samples of the burdens of obesity, 
diabetes, and other cardiovascular risk factors 
Obtain reliable in-country estimates from adequately 
sized samples of the burden of gestational diabetes 
Assess ability of country health systems to provide care 
for in-country burden of patients with diabetes
Development of a sub-Saharan African NCD research 
group and plan that includes a strategy for collaboration 
and data sharing 
Ensure that research of diabetes and other NCDs in sub-
Saharan Africa (including clinical trials) is led by 
researchers residing in sub-Saharan Africa
Leadership and 
governance
Maintain a dedicated team within the Ministry of Health 
with responsibility for overseeing country-wide, phased 
rollout of diabetes care 
Appoint a dedicated government minister with 
responsibility for developing and overseeing 
government policies to prevent obesity and overweight 
and encourage healthy lifestyles 
Maintain a dedicated team within the Ministry of Health 
with responsibility for ensuring wide-scale rollout of 
public health messages and policies to prevent and 
reverse obesity and overweight 
WHO to assemble working groups (consisting of 
practitioners, health policy makers, laboratory and 
diagnostic experts, device manufacturers, and health 
information technology companies) to produce a list of 
essential diagnostics and diagnostic equipment for NCDs 
and to create guidelines on technical standards
Integrate teams within ministries that deal with diabetes 
care and prevention into wider NCD teams 
Introduce taxation policies for sugar-sweetened 
beverages and policies to ensure all new urban 
developments are walkable 
Integration of members of teams within ministries that 
deal with diabetes care and prevention into teams 
addressing universal health coverage strategies 
WHO to assemble a working group to advise on 
information technology solutions for integrated patient 
records, which include diabetes and other NCD registries, 
and to explore future-proof and interoperable cloud-
based solutions that can be used in LMICs
··
VEGF=vascular endothelial growth factor. NCD=non-communicable disease. LMICs=low-income and middle-income countries. 
Table 1: Three levels of operational targets to 2030
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prevalence of diabetes and other risk factors of 
cardiovascular disease. In sub-Saharan Africa, 
between 1980 and 2015, the number of people older than 
20 years with a BMI of greater than 25 kg/m² increased 
from 28 million to 127 million, while the disease burden 
attributed to diabetes, as measured by disability-adjusted 
life-years (DALYs), increased by 88%.9 More than 90% of 
diabetes cases in sub-Saharan Africa are type 2 diabetes, 
suggesting that modifiable risk factors are major 
contributors to the burden of disease.10
Against this backdrop of dramatic statistics is the 
uncomfortable reality that most estimates for diabetes, 
other cardiovascular disease risk factors, and cardio-
vascular disease burden per se in countries in sub-
Saharan Africa have been modelled from generally 
poor-quality evidence using methods of defining diabetes 
that have been developed in high-income countries 
(HICs), often with European-origin populations. In the 
case of diabetes, a 2016 study11 found that nationally 
representative empirical biomarker data on diabetes 
diagnosis were not available from 21 of countries in sub-
Saharan Africa. So, although there is reasonable evidence 
that diabetes and other cardiovascular risk factors are 
increasing, the certainty of the situation is far from clear. 
Most (34 [71%] of 48 countries) of the world’s least-
developed countries are in sub-Saharan Africa.12 Thus, 
although the focus of development aid and research 
funding has so far been on infectious diseases,13,14 many 
countries are still struggling to develop health systems to 
cope with the existing infectious disease burden, which is 
much better delineated than that of cardiovascular disease 
and its risk factors. It therefore seems an impossible task 
to ask these countries—as has been requested by the 
Sustainable Development Goals (SDGs) and the UN 
high-level meeting on NCDs15—to respond to an as yet 
not accurately quantified burden of cardiovascular disease 
risk factors, using methods not yet proven to be effective 
in the region, and with little funding.
Driven by this recognition, a group of academics, policy 
makers, and clinicians met at the Rockefeller Foundation 
Bellagio Center in Italy in March, 2015, to discuss the 
state of play and potential routes forward. We centred our 
discussions on diabetes—a preventable cardiovascular 
disease risk factor—because of its multi-system 
interactions and adverse outcomes and because broad 
improvements in health-care systems are needed for its 
management. We formed The Lancet Diabetes & 
Endocrinology Commission on Diabetes in sub-Saharan 
Africa. After the meeting in Bellagio, we organised 
ourselves into working groups to look at both clinical and 
health-system elements involved in diabetes and diabetes 
care in sub-Saharan Africa. We met again at the 
World Diabetes Congress in Vancouver, Canada, in 
November, 2015, to discuss progress. The final 
Commission meeting was held at the Harvard Medical 
School Center for Global Health Delivery, Dubai, in 
February, 2016, to report results, discuss areas in which 
we had found equipoise, agree on the best approaches to 
advise in these areas, and structure the report.
Here, we present the findings of the Commission, 
including discussions of burden, and clinical, economic, 
and broader health systems, to inform the development 
of an effective response to the increasing burden of 
diabetes, other cardiovascular disease risk factors, and 
their adverse consequences. The methods used in 
sections of the report that involved novel research can be 
found in detail in the appendix 1. The narrative sections 
of the report were informed by extensive reviews of the 
literature and the knowledge and opinions of the 
Commissioners.
Burden of diabetes in sub-Saharan Africa
Globally, according to the NCD Risk Factor Collaboration 
(NCD-RisC), the number of adults with diabetes 
increased from 108 million (a prevalence of 4·7%) in 1980 
to 422 million (8·5%) in 2014—an increase in prevalence 
of 80·9%.16 Notably, diabetes prevalence in the WHO 
African region increased by 129·0% (from 3·1% in 1980 
to 7·1% in 2014; table 2).  This increase is second only to 
the WHO eastern Mediterranean region, in which the 
prevalence of diabetes increased by 132·2% (from 5·9% 
in 1980 to 13·7% in 2014; table 2).
Unfortunately, the various estimates of diabetes 
prevalence in sub-Saharan Africa have used different 
methodologies, all of which have limitations (panel 2). 
Hence, no clear data exist on the prevalence of diabetes 
in this region, which is important for planning an 
adequate health-systems response. In addition to WHO 
and NCD-RisC, other well cited estimates come from the 
International Diabetes Federation (IDF)25 and the Global 
Burden of Disease (GBD) group at the Institute for 
Health Metrics and Evaluation,9 which has produced 
estimates of deaths and DALYs due to diabetes. However, 
despite differences in methodologies, all estimates point 
to an increasing burden of diabetes in sub-Saharan 
Africa. Notwithstanding the limitations of the methods 
used to estimate diabetes prevalence (panel 2), the 
Prevalence (%) Percentage change 
for 1980–2014
Number 
(millions)
Percentage change 
for 1980–2014
1980 2014 1980 2014
African region 3·1% 7·1% 129·0% 4 25 525·0%
Region of the Americas 5·0% 8·3% 66·0% 18 62 244·4%
Eastern Mediterranean 
region
5·9% 13·7% 132·2% 6 43 616·7%
European region 5·3% 7·3% 37·7% 33 64 93·9%
Southeast Asia region 4·1% 8·6% 109·8% 17 96 464·7%
Western Pacific region 4·4% 8·4% 90·9% 29 131 351·7%
Worldwide total 4·7% 8·5% 80·9% 108 422 290·7%
Data from reference 13.
Table 2: Estimated prevalence of diabetes and number of adults aged 18 years or older with diabetes 
in 1980 and 2014, by WHO region
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The increasing impact of diabetes in sub-Saharan 
Africa is reflected in results from the 2015 GBD study,9 
which estimated that diabetes in the region caused an 
average of 145 189 deaths and 5 556 560 DALYs; DALYs 
attributable to diabetes increased by 88% between 1990 
and 2010.9 Inevitably, there is considerable imprecision 
in such estimates and other groups have produced 
different figures. For example, the IDF estimated that, 
in 2015, around 321 000 deaths in sub-Saharan Africa 
were attributable to diabetes, and that 79% of those 
deaths occurred in people aged 60 years or younger—a 
proportion higher than in any other region in the world.25
Type 2 diabetes in sub-Saharan Africa
Overview
As in other parts of the world, more than 90% of people 
living with diabetes in sub-Saharan Africa have type 2 
diabetes,10,26 which is typically associated with increasing 
age and overweight or obesity. We refer to type 2 diabetes 
simply as diabetes throughout this report, and specify 
type when referring to other types of diabetes.
Drivers of type 2 diabetes
Overweight and obesity
Traditionally, lifestyle factors leading to overweight and 
obesity, and then to diabetes, have been considered 
modifiable. However, it is now increasingly acknowledged 
that, at least at the individual level, lifestyle drivers of 
diabetes are difficult to modify; individuals have far less 
agency than was previously thought.8,27 Additionally, 
genetic predisposition to overweight, obesity, and 
diabetes—once thought to be relatively stable over 
geological timeframes—is now known to be more 
modifiable in the short term than previously considered, 
possibly via intergenerational epigenetic changes (see 
panel 3 for a discussion of genetic drivers of diabetes in 
sub-Saharan Africa). Although susceptibility to diabetes 
and its risk factors varies, the condition is largely 
avoidable with appropriate interventions.
Although not all people with diabetes in sub-Saharan 
Africa are overweight or obese by western standards, a 
rapid increase in the prevalence of overweight and 
obesity is undoubtedly a major driver of the increasing 
prevalence of type 2 diabetes in the region.9,16 The 
contribution of overweight and obesity to the variance of 
the prevalence of diabetes in sub-Saharan Africa is an as 
of yet unanswered question; some studies37–39 suggest 
that African populations might develop diabetes at lower 
body mass than people of European origin, and other 
studies in different settings40,41 have suggested that, for 
the same level of obesity, African populations are at lower 
risk for diabetes than their western counterparts. However, 
high-quality, convincing evidence is scarce.
Globally, overweight and obesity are traditionally 
considered conditions of urban rather than rural 
populations, although this situation is now in 
transition. In HICs, overweight and obesity are seen 
more in rural populations than in urban populations.21,41 
Few high-quality longitudinal studies have been done 
in Africa, but those that have been done suggest that 
the prevalence of overweight and obesity has increased 
Panel 2: Estimating the prevalence of diabetes in sub-Saharan Africa
Several different estimates exist for the prevalence of diabetes in countries in the 
sub-Saharan African region. These estimates vary depending on the method used to 
ascertain the diagnosis (eg, self-report vs biomarker) and, for biomarker-based diagnosis 
only, the biomarker used (eg, fasting glucose vs 2 h oral glucose tolerance test [OGTT] 
vs HbA1C). Even in well studied populations in high-income countries (HICs), debate 
continues around which biomarker most reliably predicts long-term macrovascular and 
microvascular outcomes of hyperglycaemia and, hence, which should be used to diagnose 
diabetes.17,18 No longitudinal studies have been done in sub-Saharan Africa to ascertain the 
best method for diagnosis. Thus, whether methods developed in HICs to determine the 
prevalence of diabetes can be used to define diabetes and reliably predict the future 
burden of clinically relevant outcomes in populations in sub-Saharan Africa is currently 
unknown. Studies in this area are urgently needed.
Compounding this uncertainty is that many countries have used the WHO STEPwise 
approach to surveillance (STEPS) method to estimate burden,5 which has included use of 
fasting glucose to diagnose diabetes. This inclusion could potentially miss patients in the 
earlier stages of the disease who would show impaired glucose tolerance in a 2 h OGTT but 
would have normal fasting concentrations. The effects of these differences in methods on 
cross-sectional prevalence estimates of diabetes have been shown in African and other 
settings.19 For example, the prevalence of diabetes in people aged 55 years and older in 
Africa was higher when measured with the 2 h OGTT than when measured with fasting 
glucose alone (23·9% vs 10·9%) and in non-STEPS studies than in STEPS studies 
(17·1% vs 9·6%).20
Results can also be affected by the sampling method used, with many country estimates 
coming from samples of convenience rather than from robust methods of sampling. 
Sample sizes also vary greatly between studies—for example, in the NCD-RisC study,16 
some countries had less than 150 data points and others had tens of thousands. 
Geography and demographics should also be considered when interpreting results. For 
example, major differences exist in the prevalence of obesity and diabetes between 
populations of young and older people.20 Additionally, although high-quality data on the 
urban versus rural prevalence of diabetes and obesity are scarce, studies from other 
countries clearly show differences in prevalence between rural and urban areas and a 
change in that distribution over time.21 Detection bias should also be considered, because 
underdeveloped health systems in countries in sub-Saharan Africa might lead to 
under-reporting of diabetes prevalence compared with HICs, where diabetes is more 
reliably detected.
These factors need to be considered when interpreting all studies of diabetes prevalence 
in countries in sub-Saharan Africa. Additionally, and importantly, all studies producing 
estimates for the region as a whole—and individual countries within that region—
are modelled and often based on little or no data. Even though we have chosen to use 
estimates from NCD-RisC16 for illustration, and recognise that this work has utility in 
making comparisons across regions and over time, the reliability of the prevalence data 
for individual countries in sub-Saharan Africa is questionable.22–24 21 countries in 
sub-Saharan Africa had missing data and, in those countries with data, samples were 
often small and data were old.
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in urban areas. For example, Ziraba and colleagues42 
used data from Demographic and Health Survey studies 
done between 1992 and 2005 in seven sub-Saharan 
African countries to show that overweight and obesity 
had increased by 35% in women living in urban areas, 
and that 31·4% of urban women were overweight or 
obese in 2005, ranging from 28–29% in Burkina Faso 
and Senegal to 38% in Kenya. However, it seems that 
the picture in sub-Saharan Africa is mixed: some 
countries show a greater prevalence of overweight and 
obesity among urban dwellers, whereas some show a 
greater prevalence in rural districts.43 This mixed 
picture is probably explained in part by differences in 
the pace of the ongoing rural transformation across 
Africa.44 Figure 1 shows our analysis of the interactions 
between diabetes and obesity in countries in sub-
Saharan Africa.
Overweight and obesity are generally associated with 
low socioeconomic status in HICs and high socio-
economic status in low-income and middle-income 
countries (LMICs), known as the reversal hypothesis.45 
However, substantial variation is seen at a more granular 
level. For example, in sub-Saharan Africa, Ziraba and 
colleagues42 found that overweight and obesity were 
more prevalent in women of low socioeconomic status 
than in women of high socioeconomic status, with the 
most rapid increase in prevalence (50% overall) seen in 
the poorest people living in urban areas; the prevalence 
of overweight and obesity declined by 10% in women 
with secondary education or higher. Conversely, Aitsi-
Selmi and colleagues46 found a positive association 
between education and obesity in two sub-Saharan 
African countries (Nigeria and Benin), and a small cross-
sectional study47 in rural Uganda suggested that obesity 
was a greater problem among those of high socio-
economic status than among those of low socioeconomic 
status. Manne-Goehler and colleagues11 found a strong 
education gradient in the self-awareness of overweight 
and obesity, suggesting that, in the long term, education 
and high socioeconomic status might be associated with 
reduced prevalence. Variation in results might also 
depend on the definitions of socioeconomic status used 
in different studies.
Such heterogeneity in results comparing urban with 
rural areas and high with low socioeconomic status is 
expected in a rapidly changing environment, but the 
paucity of high-quality studies examining these issues 
restricts any clear conclusions about links between place 
of residence, socioeconomic status, and drivers of obesity. 
The scarcity of reliable information also limits the ability 
to suggest appropriate interventions.
Poor nutrition during fetal and early life, which is 
known to contribute to obesity-related health problems 
in later life, especially when combined with subsequent 
abundance of food (the so-called thrifty phenotype48), is a 
likely problem in sub-Saharan Africa.40 Some high-quality 
evidence for this phenomenon is beginning to emerge 
from the region. For example, a study49 of 352 Malawian 
children (median age 9·3 years) who had been treated for 
severe acute malnutrition at an average age of 24 months 
showed them to have clear evidence of thrifty growth 
compared with sibling and community controls, despite 
evidence of catch-up in growth. Further research is 
needed to assess the long-term impact of intrauterine 
and childhood malnutrition in Africa.
Panel 3: Genetic drivers of diabetes
Genetics of type 2 diabetes in sub-Saharan Africa
We are not aware of any initiative that has successfully integrated genetic markers into 
clinically usable risk prediction scores (especially in low-income and middle-income 
countries) or that has used genetics to successfully improve treatment outcomes in 
diabetes. Nevertheless, genetics continues to be an area of interest both to funders and 
researchers. We question the need for such research investment in a geographical area in 
which even the burden of disease is unknown. However, given the interest in the area, 
and the possibility that knowledge of genetic susceptibility to diabetes might help define 
the scale and direction of the diabetes epidemic in Africa, we present a brief overview of 
the field in sub-Saharan Africa.
In global populations, nearly 80 genetic loci have been implicated in susceptibility to 
type 2 diabetes,28,29 and about 50% of these risk loci were replicated in a 2015 study of 
three sub-Saharan African countries enrolled in the AADM study.30 The results of that 
study suggested that the genetic architecture of type 2 diabetes in sub-Saharan Africa is 
probably characterised by several risk loci shared with populations of non-African 
ancestry, and that genetic data from Africans promise to inform the genetics of all human 
populations. Epigenetic changes have also been shown to have differential effects on 
diabetes incidence depending on the population studied, and such changes might be very 
important in African populations given early-life risks of undernutrition.31 Studies30,31 in 
sub-Saharan African populations suggest that natural selection has acted on several 
genomic regions associated with obesity and type 2 diabetes, and a study32 that mapped 
the genetic risk of type 2 diabetes by measuring the allelic frequency of 
16 diabetes-associated variants in 51 populations suggested that Africans face the 
greatest known genetic risk for type 2 diabetes of any ethnicity studied thus far.
Some knowledge gaps can also be filled by the study of African American populations, 
although such comparisons must be interpreted with caution because African Americans 
mostly originated from west or central Africa and are therefore not representative of 
sub-Saharan Africa as a whole.33 Nonetheless, African American populations clearly have a 
two-times increase in the risk of type 2 diabetes compared with Americans of European 
origin,34,35 and they also have a much higher prevalence of type 2 diabetes than most African 
populations.16 This increased risk of diabetes in African Americans might be an indication of 
future trends in Africa. Numerous initiatives linking genetics and cardiovascular risk are 
underway in sub-Saharan Africa, including the H3Africa and RODAM studies.
Genetics of type 1 diabetes in sub-Saharan Africa
Little is known about the genetics of type 1 diabetes in sub-Saharan Africa. However, a 
study36 of African American populations showed large diversity of 
HLA DRB1-DQA1-DQB1 haplotypes and genotypes in African, compared with 
European, descendants. Association analyses reproduced several type 1 diabetes risk 
effects seen in European-derived haplotypes, while also showing novel effects for 
African-derived haplotypes. In particular, the African-specific DR3 haplotype DRB1*0
3:02-DQA1*04:01-DQB1*04:02 was protective against type 1 diabetes.36 Additionally, 
the DR4/DR9 genotype, which contains an African-derived DR9 haplotype, conferred 
an odds ratio of 30·88 compared with the highest-risk genotypes found in populations 
of European origin.36 
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Cultural factors also affect the prevalence of overweight 
and obesity—for example, a large girth is perceived as a 
sign of affluence in many countries in sub-Saharan Africa 
and is a deeply rooted status symbol conferring influence, 
health, and attractiveness.50 Excess weight also has positive 
connotations in societies in which strong stigma is 
attached to weight loss and wasting associated 
with HIV/AIDS.10
25−39 years
Benin
Comoros
Guinea
Kenya
Liberia
Mozambique
Namibia
Seychelles
South Africa
Tanzania
Togo
Uganda
Overall
40−54 years
Benin
Comoros
Guinea
Kenya
Liberia
Mozambique
Namibia
Seychelles
South Africa
Tanzania
Togo
Uganda
Overall 
55−65 years
Benin
Comoros
Guinea
Kenya
Liberia
Mozambique
Namibia
Seychelles
South Aafrica
Tanzania
Togo
Uganda
Overall
A Diabetes B Overweight or obesity
Male
Female
Prevalence (%) Prevalence (%)
806040200 907050301040200 3010
Figure 1: Age-stratified and sex-stratified prevalence of diabetes and overweight or obesity among adults in 12 countries of sub-Saharan Africa 
Reproduced from Manne-Goehler and colleagues, with permission from Elsevier. Each point shows the point prevalence estimate for each age group in each country and the horizontal bars indicate 
95% CIs, except for the overall prevalence for each age group, which is also represented but as median and IQR. The data sources and methods are discussed in detail elsewhere11 and a summary is included 
in the appendix 1. Efforts to obtain, from WHO, data from the STEPwise Approach to Surveillance (STEPS) surveys done across Africa were unsuccessful.24 We therefore independently approached each 
country directly. The complete pooled dataset included 39 062 individuals from 12 countries in the period of 2004–13. (A) We calculated the prevalence of diabetes by age and sex . The surveys included 
WHO STEPS surveys done in Benin (2008), Comoros (2011), Guinea (2007–08), Liberia (2011), Mozambique (2005), Tanzania (2012), Togo (2010), and Seychelles (2013); a Demographic and Health 
Survey done in Namibia in 2013; and the South Africa Nutrition and Health Examination Survey done in 2012 (appendix 1). We defined diabetes according to the WHO criteria (appendix 1) as either a 
fasting plasma glucose concentration of 7·0 mmol/L (126 mg/dL) or higher, a 2 h plasma glucose concentration of 11·1 mmol/L (200 mg/dL) or higher, or an HbA1c measurement of 6·5% or higher. Cross-
country prevalence of diabetes ranged from 1·3% in Benin to 21·6% in Seychelles, based on fasting blood glucose measurement and self-reported use of diabetes medications. The analysis showed a strong 
association between increasing age and the prevalence of diabetes, with the prevalence reaching around 30% in men and women aged 55–64 years in South Africa and Seychelles. A higher prevalence in 
women than in men was seen across all age groups. (B) We calculated the prevalence of overweight or obesity by age and sex. Overweight or obesity was defined as a BMI of 25 kg/m² or higher. The analysis 
showed a strong association between increasing age and the prevalence of overweight or obesity, with a higher prevalence in women than in men across all age groups. Prevalence of overweight or obesity 
also varied across countries, with age-stratified levels ranging from less than 10% in men aged 25–39 years in Benin and Togo, to more than 70% in South Africa, and to almost 80% in women aged 
55–65 years in Seychelles.
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Population trends and ageing
The population aged 20–79 years in sub-Saharan Africa is 
projected to increase from 441 million in 2015 to 
926 million in 2040.51 Given the association between 
diabetes and older age, this increase will be an important 
driver of the increase in the number of people with 
diabetes. Furthermore, increasing life expectancy is a 
notable feature of populations in sub-Saharan Africa, 
especially in countries with a high HIV prevalence and in 
which life expectancy is increasing with the rollout of 
antiretroviral therapies.52 Although large-scale, high-
quality studies from sub-Saharan Africa are scarce, a 
2016 systematic review20 of studies published between 2000 
and 2015 estimated the prevalence of diabetes to be 13·8% 
(95% CI 13·2–14·3) in those aged 55 years or older. Given 
the potential impact of an ageing population on the 
prevalence of diabetes in sub-Saharan Africa, it is essential 
for health-system planning that high-quality, local 
information is obtained on the association between ageing 
and diabetes. See figure 1 for an analysis of the association 
between diabetes and age in sub-Saharan Africa.
Type 1 diabetes in sub-Saharan Africa
Type 1 diabetes can occur at any age, with a peak onset 
around the time of puberty in western countries. A later 
peak from around 15–25 years is often reported in 
Africa.53 With increasing age, the clinical distinction 
between types of diabetes can also seem blurred, which 
further compounds the issue of ascertaining the true 
lifetime prevalence of type 1 diabetes.
The incidence of type 1 diabetes began to rise in western 
populations around the middle of the last century, and is 
still increasing in many parts of the world.54 The rapidity 
of this increase points to environmental causes 
superimposed upon genetic susceptibility. For example, 
Ethiopian immigrants to Israel developed type 1 diabetes 
at higher rates than their counterparts in Ethiopia; this is 
thought to be due to genetically predisposed individuals 
being exposed to new environmental triggers in Israel.55 
Earlier age of onset is associated with higher degrees of 
genetic susceptibility (panel 3), and the secular trend 
towards earlier onset in western populations suggests 
increased penetrance of the disease; a similar shift has 
also been reported in Rwanda.56
The incidence of type 1 diabetes varies widely with 
geography, and a difference in the incidence of childhood 
type 1 diabetes of more than 350 times between 
populations has been described (from an age-adjusted 
incidence of 0·1 per 100 000 population per year in China 
to 36·8 per 100 000 population per year in Sardinia).57 
Therefore, the incidence from one area cannot be easily 
extrapolated to another. Unfortunately, information about 
prevalence and incidence from sub-Saharan Africa is 
scarce. For example, estimates used in the 2015 IDF Atlas25 
were extrapolated from studies in only five countries 
(Ethiopia, Nigeria, Rwanda, Tanzania, and Zambia). From 
the existing evidence, it seems that the incidence of type 1 
diabetes in sub-Saharan Africa is relatively low compared 
with many other parts of the world. However, small poor-
quality studies, and the limited ability of health systems to 
diagnose the condition, means that the true prevalence 
remains obscure.58 Indeed, recent evidence from Rwanda 
suggests that the low apparent prevalence of type 1 
diabetes in sub-Saharan Africa is very likely to represent 
failure of diagnosis or high mortality in diagnosed cases, 
because numbers increase sharply when interventions 
become available (see appendix 2 for profile of Rwanda).59,60 
An additional limitation of studies is that estimates have 
generally focused on children younger than 15 years and 
therefore do not account for a substantial proportion of 
people with disease onset after this age. The only 
published prevalence figure to cover the entire young 
adult age group came from Rwanda and was 16·4 per 
100 000 population younger than 26 years.61,62 In Rwanda, 
there are 3·5 times as many cases of type 1 diabetes in the 
population younger than 26 years as in the population 
younger than 15 years.
Other forms of diabetes in sub-Saharan Africa
Other forms of diabetes in the region might constitute a 
greater proportion of cases than the 5% seen in HICs.26 
Of particular note, in Ethiopia, many cases of diabetes 
that had previously been considered to be type 1 are now 
being reconsidered in light of antibody studies that have 
not shown the presence of antibodies typical of the 
disease.53
Malnutrition-related diabetes has been reported in sub-
Saharan Africa, but its classification as a distinct subtype 
has been controversial, despite several cases being 
reported in the literature.50,53 Also known as fibrocalculous 
pancreatic diabetes, malnutrition-related diabetes is 
usually seen in underweight, malnourished patients and 
is characterised by severe hyperglycaemia without 
ketosis, high insulin requirements, and the absence of 
autoimmunity.
Variant forms of diabetes have been described in people 
of African descent since the 1950s. Reports from African 
American populations indicate that so-called variant 
diabetes is seen in new-onset patients, typically middle-
aged, overweight, and with a family history of type 2 
diabetes in 80% of cases. Despite presentation with 
ketosis, such individuals can usually be managed without 
insulin.63 The extent to which this represents a true 
variant of diabetes remains uncertain, and it is clear that 
there is the need for more detailed investigation of the 
pathophysiology of diabetes in people of African descent.
We discuss gestational diabetes in sub-Saharan Africa 
in panel 4.
Complications of diabetes
Overview
As discussed extensively in panel 2, there is insufficient 
high-quality evidence to estimate the burden of diabetes 
in sub-Saharan Africa or to obtain reliable data about 
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For more on the RODAM study 
see http://www.rod-am/eu/
content/objectives
See Online for appendix 2
Panel 4: Gestational diabetes and hyperglycaemia in pregnancy
Causes
Relative insensitivity to insulin is a normal feature of pregnancy 
and gestational diabetes occurs when pregnancy results in 
overt hyperglycaemia. Because a fetus exposed to 
hyperglycaemia overproduces insulin, which can lead to 
macrosomia, obstetric difficulties might result.64 In addition to 
being caused by gestational diabetes, hyperglycaemia in 
pregnancy might also be due to pre-existing diabetes or 
diabetes that manifests for the first time during pregnancy.
Maternal BMI and risk of gestational diabetes are highly 
correlated,65 and hyperglycaemia in pregnancy is becoming 
increasingly common in parallel with the increased prevalence 
of diabetes and obesity in the background population. 
Increasing global trends in maternal overweight and obesity 
have been reviewed extensively by Poston and colleagues.65 
In sub-Saharan Africa, Demographic and Health Surveys show 
wide variation in the prevalence of obesity in women of 
childbearing age, ranging from 0·7% in Madagascar to 26·8% in 
Lesotho. Although maternal underweight has previously been 
of great concern in the region, it is now less common than 
excess weight in women of childbearing age.66
Prevalence
The global prevalence of hyperglycaemia in pregnancy was 
estimated to be 16·9% in 2013, equating to 21·4 million 
livebirths.65 More than 90·0% of cases were estimated to occur 
in low-income and middle-income countries, and 16·0% were 
attributed to pre-existing diabetes or diabetes manifesting for 
the first time during pregnancy, leaving around 64·0% due to 
gestational diabetes. However, the prevalence might vary by 
region depending on the diagnostic criteria used.67 
Unfortunately, studies reporting the different causes of 
hyperglycaemia in pregnancy in sub-Saharan African countries 
are rare.
Scarce information exists about the prevalence of gestational 
diabetes in sub-Saharan Africa. A 2014 systematic review67 of 
gestational diabetes in the African continent found a 
prevalence of gestational diabetes ranging from 0% in Tanzania 
to 13·9% in Nigeria. The authors comment that “it is alarming 
that very little appears to be known about gestational diabetes 
in Africa”, and only six countries (five in sub-Saharan Africa) 
provided data of sufficient quality for inclusion in the review.67 
Additionally, diagnostic criteria differed between studies and 
increased prevalence was seen in studies done after the year 
2000 and in those that used more current diagnostic criteria.
Diagnosis of gestational diabetes 
It is recommended that screening for gestational diabetes is 
done between 24 weeks and 28 weeks of gestation with the 
75 g oral glucose tolerance test (OGTT). However, differences 
exist between organisations’ diagnostic criteria for gestational 
diabetes, and criteria for gestational diabetes have changed 
over time.67 This variation in criteria makes comparing studies 
and synthesising results from studies challenging, both within 
sub-Saharan Africa and globally. For example, a study68 of 
around 1000 pregnant women screened for gestational 
diabetes between 24 weeks and 34 weeks of gestation in a 
single clinic in Nigeria with the OGTT found the prevalence of 
gestational diabetes to be 3·8% when 1999 WHO criteria69 
were used, 8·1% when 2013 WHO criteria70 were used, and 
8·6% when International Association of Diabetes and 
Pregnancy Study Groups Consensus Panel (IADPSG) criteria71 
were used.
After the results of the HAPO study72 were reported in 2008, 
many groups revised their guidelines. In particular, the IADSPG 
and WHO 2013 (similar to IADSPG) criteria differ from older 
criteria or those used by other organisations; only one 
abnormal value, rather than two, is needed to diagnose 
gestational diabetes, and the fasting glycaemic thresholds 
used to diagnose glycaemia are lower than previous criteria.67 
The new criteria will probably result in an increased prevalence 
of gestational diabetes, with knock-on effects on burden to 
health systems. For a full review of the diagnostic criteria for 
gestational diabetes, see the review by Ma and colleagues.64 It 
should also be noted that the HAPO study—on which the 
IADSPG and WHO 2013 criteria are based—investigated 
outcomes of hyperglycaemia in pregnancy in a non-African 
population, and outcomes might be different in populations 
that are distinct from the original study population.73 Further 
research is needed to ascertain whether the new IADSPG and 
WHO 2013 criteria are applicable to populations in 
sub-Saharan Africa in terms of their ability to predict adverse 
maternal and offspring outcomes.
Risk factors for gestational diabetes in sub-Saharan Africa, as 
elsewhere, are gestational diabetes in a previous pregnancy, 
family history of type 2 diabetes, previous stillbirth or child with 
macrosomia, and maternal age of 30 years or older. It is not 
clear whether sub-Saharan African women are at increased risk 
of gestational diabetes compared with other ethnic groups. In a 
multi-ethnic society such as the USA, women from southeast 
Asia were found to develop gestational diabetes at lower BMI 
than women of European, Hispanic American, or 
African American origin, and it was estimated that two-thirds 
of gestational diabetes cases in African Americans could be 
prevented if all women were of normal weight when they 
entered pregnancy.74
Complications and treatment of hyperglycaemia in pregnancy
Complications include pregnancy-induced hypertension and 
pre-eclampsia, antepartum haemorrhage, complications of 
labour, preterm birth, birth trauma, congenital anomalies, and 
high perinatal mortality.64,65 Women with gestational diabetes are 
at a high risk of developing subsequent type 2 diabetes, and their 
offspring have increased susceptibility to glucose intolerance and 
obesity later in life. Additionally, the risk of diabetic retinopathy 
during pregnancy is nearly twice that in the non-pregnant state.75 
The rate of complications is greater in pregnancies with pre-
existing diabetes than in those without.64,65,76
(Continues on next page)
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trends over time. The same is true when considering the 
burden of diabetes-related complications. In particular, 
detection bias probably has a large effect on the reporting 
of complications of diabetes in countries where health 
systems are not sufficiently developed to provide high-
quality services, and where health-care-seeking behaviour 
is low. Additionally, evidence suggests that hyperglycaemia 
in patients in sub-Saharan Africa is detected at a later 
stage than in patients in HICs.10 Therefore, given the 
longer lead time of hyperglycaemia before treatment is 
given, patients in sub-Saharan Africa might appear more 
susceptible to complications than their peers in other 
countries. A scarcity of data systems in many countries is 
a major hurdle to adequate documentation of 
complication rates; WHO found that only 17% of 
countries in sub-Saharan Africa had any form of diabetes 
registry (although WHO did not report the geographical 
coverage of, or the quality of, information in those 
registries).83 Additionally, the quality of the data reported 
will inevitably vary in line with the ability of health 
services to record and retrieve information related to 
complications of diabetes. Although we present in the 
sections below the highest-quality evidence available for 
illustrative purposes, the evidence is probably not a good 
representation of complications in the entire region. We 
do not discuss interactions between diabetes and 
infectious diseases, which are of particular relevance to 
sub-Saharan Africa, where high rates of infectious disease 
coexist with an increasing prevalence of NCDs including 
diabetes. These interactions have been extensively 
reviewed elsewhere;84–87 comprehensive coverage of these 
areas are beyond the remit of this Commission.
Death
The 2015 GBD study9 estimated that, in 2013, diabetes 
contributed to an average of 145 189 deaths (uncertainty 
interval 129 914–164 809) in sub-Saharan Africa, which 
amounted to 1·8% (1·68–1·97) of all deaths in the region. 
These figures should be interpreted with caution given 
the inadequate recording of cause of death in sub-
Saharan Africa. Indeed, given the prevalence of diabetes 
in the region, and the inadequacy of many health systems 
to effectively diagnose and treat diabetes and its 
complications, this estimate seems very low.
Little is known about the causes of death due to chronic 
complications of diabetes in sub-Saharan Africa.10 This 
knowledge deficit is due to the scarcity of high-quality 
vital registration systems in sub-Saharan Africa and poor 
diagnostic facilities. Some countries in the region use 
verbal autopsies in sample populations to determine the 
cause of death, which give estimates at the population 
level. A 2014 study88 from the INDEPTH network of 
Health and Demographic Surveillance System sites 
suggested that diabetes contributed little to mortality 
caused by NCDs in Africa compared with that caused by 
cardiovascular diseases and cancers. However, this 
method might not have captured diabetes as a contributor 
to death if it was not ascertained as a direct cause of death.
There is also insufficient data from the region on acute 
mortality due to diabetes, although the Commissioners’ 
experiences and opinions suggest that acute mortality 
caused by diabetes in sub-Saharan Africa is most often 
due to undiagnosed or inadequately treated type 1 
diabetes, which rapidly progresses to diabetic ketoacidosis 
and death. Early reports from sub-Saharan Africa 
document a very high mortality for type 1 diabetes. In 
Mali during the 1990s, 50% of patients died within 2 years 
of a type 1 diabetes diagnosis,89 and a study90 published in 
2005 estimated the life expectancy of children younger 
than 15 years in Mozambique to be 3·5 years after 
diagnosis; a child in a rural area who developed diabetes 
was unlikely to survive for more than 1 year. Data on 
mortality of people with type 1 diabetes from some other 
countries suggested less severe outcomes. In Soweto, 
South Africa, mortality due to type 1 diabetes was 16% in 
the period of 10 years between 1982 and 1992 (with half of 
the deaths being from renal failure and the remaining 
deaths being from ketoacidosis, hypoglycaemia, or 
sepsis), although a follow-up study showed 43% mortality 
after 20 years of follow-up.81 Data from Rwanda in 2015 
suggested a 5 year survival of 93·8%.25 However, it is 
unlikely that these data reflect the true mortality of type 1 
diabetes in Rwanda because a substantial amount of data 
were missing and participants could potentially have 
been subject to the Hawthorne effect. It is possible that 
mortality for type 1 diabetes in Rwanda could have been 
as high as three times the crude mortality rate of 13·9 per 
1000 patient-years.25
Relatively little is known about the maternal or offspring 
outcomes of pregnancy in women with pre-existing diabetes in 
sub-Saharan Africa, other than from a few previous studies,77–79 
which had small sample sizes or were published years ago and 
so have little relevance to the current situation in the region. 
The increasing prevalence of obesity, and its associations with 
gestational or type 2 diabetes, in women who are of 
reproductive age, could have a great impact on both women 
and their offspring. That so little is known about these issues in 
sub-Saharan Africa is cause for serious concern.
Treating hyperglycaemia during pregnancy in women in 
sub-Saharan Africa might be no different to treating women in 
other countries. However, all studies identified by this 
Commission about the management of hyperglycaemia in 
pregnancy in sub-Saharan African populations have been 
observational;78,80–82 randomised trials comparing treatments in 
sub-Saharan Africa are urgently needed.
(Panel 4 continued from previous page)
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Although reliable data from sub-Saharan Africa are not 
available, the small number of studies that have been 
done can still be taken to reflect a state of care that is far 
below standards seen in more affluent parts of the world, 
where life expectancy for young people diagnosed with 
type 1 diabetes is now only a few years less than that of 
the general population.91
Chronic complications of diabetes
The chronic complications of diabetes affect blood 
vessels and are conventionally subdivided into 
macrovascular and microvascular; however, they also 
affect other tissues, including nerves and the optic lens. 
Little is known about the prevalence, age of onset, or 
rate of progression of diabetic complications in sub-
Saharan Africa, and most evidence comes from small, 
single-country, single-centre, and somewhat out-of-date 
studies. A systematic review92 that used GBD methods 
calculated that the non-fatal burden of diabetes in total 
years lost due to disability in South Africa in 2009 
was 73 714; 42 919 (58·2%) from diabetes alone, 
13 458 (18·3%) from retinopathy, 4527 (6·1%) from 
amputations, 7233 (9·8%) from attributable stroke 
disability, and 5577 (7·6%) from attributable ischaemic 
heart disease disability. Additionally, the GBD 2015 
study9 estimated that diabetes contributed to 5 556 560 
(uncertainty interval 4 753 194–6 442 898) DALYs in 2013, 
which corresponded to 1·05% (0·94–1·16%) of all 
DALYs in sub-Saharan Africa. Such estimates are 
necessarily imprecise and, as previously discussed, 
seem low given the estimated prevalence of diabetes in 
sub-Saharan Africa and the poor access to health 
systems for management of hyperglycaemia.
The scarcity of reliable data is highlighted as a 
limitation in all reports of specific complications in sub-
Saharan Africa. For example, a 2011 systematic review26 
of the prevalence of chronic complications of diabetes in 
the region found only 23 eligible studies. The recorded 
prevalence of retinopathy varied from 7% in Kenya 
to 63% in South Africa, of neuropathy from 27% in 
Cameroon to 66% in Sudan, and of microalbuminuria 
from 10% in Tanzania to 83% in Nigeria. Macrovascular 
complications were not covered, and a search of the 
literature done by the Commission did not return any 
studies addressing the prevalence of cardiovascular 
complications. The most recent regional narrative review 
was done by Levitt10 in 2008, who noted that ischaemic 
heart disease was less common in indigenous Africans 
with diabetes (5–8% based on electrocardiogram stress 
tests and 4% based on history) than in their counterparts 
of European heritage (23% based on positive history). 
Levitt also noted that there was little available evidence 
on the risk of stroke in people with diabetes.
The available information indicates that vascular 
complications develop sooner after a diabetes diagnosis 
in sub-Saharan African patients than in those from other 
parts of the world,10 which is an inevitable consequence 
of late diagnosis and poor glucose control. Thus, if 
reliable evidence was available, we suspect that the 
prevalence and severity of complications of diabetes in 
the region would far surpass reports from studies of 
HICs. This deduction is of concern, given that health 
systems in sub-Saharan Africa are already struggling. 
Diabetic eye disease
The manifestations of diabetes that affect sight are 
diabetic retinopathy, proliferative retinopathy, and 
maculopathy, all of which are preventable and treatable 
before vision is lost.93 Cataracts are prevalent among 
patients with diabetes in Africa, but much of the 
literature has focused on diabetic retinopathy, which is 
where we focus our discussion.
Globally, diabetic retinopathy accounts for 2·6% 
(95% CI 2·2–3·4) of all blindness,94 and age-standardised 
prevalence of retinopathy as a cause of blindness was 
found to be highest in sub-Saharan Africa, at 0·14% 
(0·10–0·20).94 The most up-to-date systematic review95 of 
the prevalence of diabetic retinopathy in people with 
diabetes in sub-Saharan Africa was published in 2013. The 
authors of that review95 included 62 studies from 
21 countries in the region and, accepting recognised 
differences in diagnoses and sampling techniques, the 
prevalence in population-based surveys was 30·2–31·6% 
for diabetic retinopathy, 0·9–1·3% for proliferative 
diabetic retinopathy, and 1·2–4·5% for any maculopathy. 
Those numbers were roughly similar to the global 
reported prevalence,96 which is surprising given the poor 
access to services for the diagnosis and treatment of 
hyperglycaemia in sub-Saharan Africa, although it is likely 
that poor access to health systems and reporting in sub-
Saharan African populations result in underestimation of 
prevalence.
Diabetic nephropathy
Globally, the contribution of chronic kidney disease to 
deaths nearly doubled between 1990 and 2010, although 
improved ascertainment and ageing populations might 
have contributed to this increase.97 In 2010, 70% of 
patients with end-stage renal failure were predicted to 
live in low-income countries (LICs). Hypertension was 
the leading cause of death from kidney disease worldwide 
in 2010,97 but the number of cases attributable to 
hypertension was decreasing by 2013, whereas cases 
attributable to diabetes were increasing.98
The true prevalence of both chronic kidney disease and 
diabetic nephropathy in sub-Saharan Africa remains 
uncertain because of the lack of population-based surveys 
and diabetes registries. However, evidence from a 
systematic review and meta-analysis99 of studies involving 
64 307 people estimated the prevalence of chronic kidney 
disease in sub-Saharan Africa to be 13·9% (95% CI 
12·2–15·7). The mean age of people in that study99 was 
41·4 years (SD 9·9); 46 494 (72%) people had diabetes, 
2765 (4%) were obese, 37 169 (58%) were HIV-positive, 
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and 7845 (12%) had hypertension. These findings should 
be interpreted with caution, since only three of 90 studies 
were considered high quality. Notably, the estimated 
prevalence of diabetes was decreased to 6% in the 
21 studies deemed of medium or good quality.99,100 Similar 
caution is needed with regards to evidence about the 
prevalence of nephropathy in patients with diabetes, 
which has in most studies been based on the presence of 
proteinuria. A systematic review101 identified 32 studies 
from 16 African countries, only two of which were 
population-based. That study suggested a prevalence of 
proteinuria in patients with diabetes as high as 95% at 
10 years of follow-up, with an 18·4% mortality from 
nephropathy at 20 years of follow-up.
Studies102 have shown that African Americans have 
twice the risk of end-stage renal disease compared with 
people of European descent, even after correction for 
socioeconomic and clinical risk factors. This increased 
risk appears to be due in part to inheritance of an 
apolipoprotein L1 (APOL1) gene variant, of which the 
high prevalence in west Africa might have been driven by 
selection for the protection it confers against some 
variants of trypanosomiasis.102 APOL1 has been associated 
with accelerated progression of several types of renal 
disorder, including increased susceptibility to HIV-
induced nephropathy, and might have a similar role in 
diabetic nephropathy.103 When factors such as 
hypertension, HIV, genetic predisposition, and diabetes 
are combined, as is often the case, renal damage is likely 
to be accelerated.104 In fact, the average age of onset of 
end-stage renal disease in sub-Saharan Africa is 
estimated to be 20 years younger than that in HICs.104
Diabetic neuropathy and diabetic foot
Diabetic peripheral neuropathy is probably the most 
common complication of diabetes globally, affecting more 
than 50% of patients with diabetes.105,106 However, estimates 
vary depending on the diagnostic and epidemiological 
methods used. Diabetic peripheral neuropathy can be 
painless or, less commonly, painful.107 Although well 
designed, large, up-to-date, population-based studies are 
not available, and this summary should be interpreted 
with that in mind, published data from countries in sub-
Saharan Africa suggest that diabetic peripheral neuropathy 
is common in the region.105 In the USA, the prevalence of 
diabetic foot ulcers was estimated to be 8% of patients 
with diabetes,108 whereas the prevalence in sub-Saharan 
Africa is thought to be higher. For example, the prevalence 
of diabetic foot ulcers was estimated to be 15% in 
Tanzania,109 13% in Cameroon,110 and 9·5% in Nigeria.111 In 
hospitalised patients with diabetes, as would be expected, 
the prevalence of diabetic foot ulcers is even higher,110,111 
although limitations of study size apply. The clinical 
features of painful diabetic peripheral neuropathy are 
similar to those in patients outside of sub-Saharan Africa 
and include poor quality of life, insomnia, and 
depression.112
Although, once again, evidence is sparse and not 
recent enough to draw clear conclusions, peripheral 
neuropathy is thought to be the principal underlying 
risk factor for foot ulceration in patients with diabetes 
in sub-Saharan Africa.113,114 This differs from HICs, in 
which peripheral arterial disease is closely associated 
with the development of diabetic foot disease.115 The 
pattern seems to be changing, however, with the 
prevalence of peripheral arterial disease increasing 
rapidly in people with diabetes in sub-Saharan Africa. 
Compared with a prevalence of less than 10% in 
the 1990s, more recent studies have shown an increased 
prevalence of peripheral arterial disease of between 20% 
and 54%.116–118
In addition to diabetic peripheral neuropathy and 
peripheral arterial disease, multiple environmental 
factors are associated with both the occurrence and 
severity of diabetic foot disease—for example, bare-foot 
walking (which might be cultural or related to an inability 
to afford shoes); ill-fitting shoes; or rodent bites on feet, 
particularly in people who sleep on the floor.113,119
In sub-Saharan Africa, amputations are frequent 
outcomes in patients with diabetic foot ulcers. Around a 
third of such amputations have been associated with 
neuro-ischaemic lesions, progressive infection, or both.120 
The in-hospital mortality of patients with severe foot 
ulcers (Wagner score >4) managed without surgery or 
amputation can be as high as 54%.121 Amputation rates 
might also be lower than expected because of difficulty in 
obtaining consent for surgery. Sadly, some patients with 
severe diabetic foot ulcers discharge themselves from 
hospital against medical advice, putting themselves at 
high risk of severe sepsis and death at home.
Arterial disease
Cardiovascular disease is modulated by three major 
preventable risk factors other than smoking (the 
prevalence of which is increasing rapidly in Africa122,123): 
hypertension, diabetes, and hyperlipidaemia. Although 
obesity largely manifests risk through its effects on these 
factors, it is still classed by many investigators as a 
modifiable risk factor of cardiovascular disease and is 
thus included in this discussion. Together, these risk 
factors are thought to account for most deaths from 
cardiovascular causes. According to GBD,97 hypertension 
remains the leading risk factor worldwide, but diabetes 
(and obesity) replaced cholesterol in second place 
between 1980 and 2010 for all categories other than 
ischaemic heart disease, with the mortality burden 
shifting from HICs to LMICs. In sub-Saharan Africa, 
obesity and hypertension are thought to be the most 
common cardiovascular risk factors, although issues of 
insufficient reliable data apply.124 We have discussed 
obesity earlier in this report. The prevalence of high 
blood pressure has increased rapidly in the past 
2–3 decades and, according to the WHO STEPwise 
approach to surveillance (STEPS) surveys done in 
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sub-Saharan Africa,125 the prevalence of high blood 
pressure ranges from 19·3% in Eritrea to 39·6% in 
Seychelles. It is estimated that 150 million people living 
in sub-Saharan Africa will be treated for hypertension by 
2025 compared with 80 million in 2010, an increase 
attributed to excessive alcohol consumption, reduced 
physical activity, and adoption of western diets and other 
features of the economic transition.125
The extent of co-association of cardiovascular risk 
factors in individuals with diabetes is even less well 
known. Recent studies have estimated that, among 
patients with diabetes in sub-Saharan Africa, the 
prevalence of hypertension ranges from 44% to 76%.126–129 
Little is known about the prevalence of hyperlipidaemia 
in patients with diabetes in sub-Saharan Africa, and the 
prevalence of metabolic syndrome among people with 
diabetes in clinical settings in the region ranged 
from 25% to more than 90%, depending on the criteria 
used.130 Insufficient high-quality information is also a 
major limitation when reviewing the features of people 
presenting with cardiovascular disease in sub-Saharan 
Africa. For example, a systematic review131 of myocardial 
infarction in the region found only seven studies from 
five countries that satisfied all inclusion criteria. 
Nevertheless, information from another review132 
illustrated the heterogeneity of risk factors in patients 
presenting with coronary disease: 41·0–66·3% for 
hypertension, 22·5–40·0% for diabetes, 8·8–67·3% for 
hyperlipidaemia, 11·8–44·0% for smoking, and 
27·0–80·0% for obesity. Sample size was exceedingly 
small in all the studies included in the review,132 ranging 
from 30 patients to 169 patients, probably reflecting the 
inadequacy of record keeping and storage.
A worrying feature of the changing pattern of 
cardiovascular disease in sub-Saharan Africa is the 
proportion of deaths in people younger than 70 years, 
which is still increasing in the region despite decreasing in 
many HICs; deaths attributed to cardiovascular disease in 
people younger than 70 years contributed to 21% of total 
deaths in HICs compared with 58% of total deaths in sub-
Saharan Africa in 2013.9 Thus, cardiovascular disease 
seems to be affecting younger, more economically 
productive people in sub-Saharan Africa. The scale of the 
cardiovascular disease epidemic likely to affect sub-
Saharan Africa awaits clearer definition, and so too does 
the pattern. However, cerebrovascular disease is likely to 
contribute substantially to the burden of cardiovascular 
disease given that it is thought to be responsible for 
around 11·23% (95% CI 10·92–11·57) of all deaths 
worldwide.9 Stroke is potentially preventable, and a 
systematic review133 of worldwide stroke incidence showed 
a 42% reduction in incidence in HICs in the four decades 
from 1970 to 2008. By contrast, the incidence of stroke has 
increased by 100% in LMICs.133 Little is known about the 
prevalence of stroke in patients with diabetes in sub-
Saharan Africa, although early reports suggest that it is 
low. For example, in a large study134 covering the period 
from 1999 to 2012 in a major hospital in urban Cameroon, 
and involving 1688 patients admitted for stroke, the 
prevalence of diabetes was 12·8%. However, the prevalence 
is likely to vary greatly depending on geographical location.
Clinical challenges of diabetes in sub-Saharan 
Africa
Diagnosing diabetes in sub-Saharan Africa
The clinical challenges of diabetes in sub-Saharan Africa 
are numerous, yet, despite differing levels of development 
and population structure, countries within the region face 
similar challenges concerning screening, diagnosis, and 
management. In this section we consider issues of clinical 
relevance, wherein common themes in the inability to 
provide quality care are scarcity of knowledge, inability to 
reliably access drugs, and poor access to treatments for 
complications. Health system considerations will be 
addressed in more detail in subsequent sections.
Poor awareness of diabetes, both at population and 
health-care-profession levels, means diagnosis is often 
delayed. For people with type 2 diabetes, this delay will 
generally result in an unequivocally elevated random 
glucose at presentation.10,39,135 Choosing the correct cutoff 
point or test to use for diagnosis of diabetes (panel 2) is 
therefore of less immediate relevance in the context of 
routine clinical diagnosis and care in this setting, but the 
question of whether the American Diabetes Association 
(ADA) guidelines136,137 for diagnosis of diabetes can be 
applied to a sub-Saharan African population will become 
increasingly important in the future as earlier detection 
of diabetes becomes feasible. It is worth noting that, 
although HbA1c is increasingly used as a diagnostic tool 
in HICs, its use is likely to face challenges in Africa given 
that it relies on integrity of red blood cells, which can be 
affected by several conditions that are prevalent in sub-
Saharan Africa, such as haemolysis from malaria or 
sickle cell disease.
Diagnosis of diabetes is complicated by the poor 
availability of diagnostic equipment in clinics, laboratory 
facilities to process samples, and transport between 
clinics and laboratory facilities (table 3). Therefore, 
rather than rely on the gold-standard measures put 
forward by the ADA, many practitioners rely on capillary 
blood glucose measurements made with point-of-care 
instruments and urine strips. However, even these 
simple tests are often unavailable. For example, Beran 
and colleagues90,139 found that urine glucose strips were 
available in only 18% and blood glucose meters in only 
21% of health-care facilities in Mozambique. Blood 
glucose meters were available in 13% (urine glucose 
strips in 54%) of facilities in Mali and in 49% (urine 
glucose strips in 61%) of facilities in Zambia.90,139
For people with type 1 diabetes, a delay in diagnosis can 
prove fatal. Unfortunately, given that in LICs the 
symptoms of type 1 diabetes—rapid weight loss, fatigue, 
abdominal pain, and confusion—can easily be mistaken 
for AIDS or cerebral malaria,140,141 and that the condition is 
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relatively rare, anecdotal reports and small studies suggest 
that diagnosis is often delayed. Indeed, Makani and 
colleagues141 found that 21 (11%) of 199 patients diagnosed 
with cerebral malaria in Tanzania actually had diabetes.
We discuss diagnosis of gestational diabetes in panel 4.
Managing hyperglycaemia in sub-Saharan Africa
Effective glycaemic control is essential for short-term 
wellbeing and long-term protection against 
complications. Available evidence suggests that many 
people with diabetes in sub-Saharan Africa fail to achieve 
adequate glycaemic control, although studies specifically 
addressing this issue have been small.142–144 Good 
glycaemic control is most likely to be achieved when a 
patient has reliable access to clinical services, when the 
availability of equipment to monitor control is good, 
when patients and health-care professionals have good 
knowledge about diabetes management, and when 
efficacious and affordable treatment is available and 
backed by adequate and effectively deployed measures of 
glucose control. In sub-Saharan Africa, barriers are 
experienced at each of these steps. Manne-Goehler and 
colleagues11 found that only around one-fifth of 
overweight or obese people at high risk of diabetes 
remembered ever being offered blood glucose testing, 
that just over one-third of those who were identified as 
having diabetes remembered ever having a test done, 
and that only one-quarter were on medication.
The ability to monitor glycaemic control per se in sub-
Saharan Africa is difficult, even in hospital settings. For 
example, in a survey of six countries done in 2011,128 only 
around 47% (range 27·5–81·1) of patients with diabetes 
had had HbA1C measured in the 12 months before the 
study. In primary care settings, the situation is probably 
worse; however, we could not find any published data 
from sub-Saharan Africa. The availability of other 
methods for measuring glycaemia in the clinical setting 
was discussed earlier. As discussed in panel 2, the choice 
of test to monitor long-term glycaemic control is a key 
consideration and, although HbA1C is the test of choice in 
many centres in sub-Saharan Africa,39 whether 
measurement of HbA1C is the best test for a sub-Saharan 
African population is unclear. Other methods of 
monitoring glycaemic control, such as measuring 
concentrations of fructosamine or glycated albumin,17 
might be beneficial in populations for whom HbA1c is not 
reliable. These tests are not, however, widely available in 
sub-Saharan Africa, and their potential value in the 
region needs to be explored further.
Limited access to home blood glucose monitoring 
equipment adversely affects patient education and 
empowerment, which is a mainstay of diabetes 
management.145 The median cost of a blood glucose strip 
in seven African nations was US$0·50 (range $0·20–$1·20), 
and the yearly cost of consumables for minimal reasonable 
care to families with a child or young person with diabetes 
in these countries ranged from 74% to 377% (median 126%) 
of per-capita gross national income.146
The first step of type 2 diabetes treatment in HICs is 
lifestyle advice, but few patients in sub-Saharan Africa 
receive such advice. Additionally, most people with type 2 
diabetes require drug treatment, with the most 
commonly available drugs being metformin and 
sulfonylureas, or insulin for those who do not respond to 
treatment with these drugs. Affordability should not, in 
principle, be an obstacle to treatment, since these drugs 
are potentially available at low cost. Unfortunately, as 
discussed later in this report, supply-chain problems and 
price mark-ups are such that simple therapies are often 
unavailable or unaffordable at the patient level.
Newer and more expensive treatments are actively 
marketed in all parts of the world147 and might have 
advantages in certain subgroups of patients,148 although 
there are few outcome studies to show that they can 
Cost per 
person with 
diabetes(U$)*
Facilities offering 
diabetes 
management*
Readiness to 
provide diabetes 
services†
Guidelines 
available to 
treat diabetes*
At least one 
trained member 
of staff*
Blood 
glucose 
testing*
Urine 
dipstick 
proteins*
Urine 
dipstick 
ketones*
Metformin 
capsules*
Glibenclamide 
capsules*
Injectable 
insulin*
Benin (2013) 73·0 33% 44% 10% 5% 31% 52% 26% 22% 29% 7%
Burkina Faso 
(2012)
91·0 42% 43% 27% 19% 14% 70% 25% 6% 6% 4%
Kenya (2013) 82·4 37% .. .. .. .. .. .. .. .. ..
Mauritania 
(2013)
89·6 17% .. 38% 16% 25% 33% 26% 9% 8% 12%
Sierra Leone 
(2012)
184·4 23% 51% 25% 6% 43% 82% 64% 46% 35% 20%
Tanzania 
(2012)
95·5 12% 51% 30% 34% 40% .. .. 57% 52% 34%
Uganda 
(2013)
No estimate 34% 60% 83% 31% 80% 61% .. 49% 55% 15%
Zambia (2010) 186·6 32% 57% 43% 20% 51% 67% .. 36% 70% 39%
Data are % of facilities unless otherwise specified. Income status for each country (all are low income) was determined by data from the World Bank (2014).138 *Data are from country Service Availability Readiness 
Assessment reports. †Data are from the International Diabetes Federation 2015 Diabetes Atlas.25 
Table 3: Service delivery indicators for facilities offering diabetes diagnosis, management, or both, by low-income country
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achieve cost-effective reductions in morbidity or mortality 
compared with the three basic medications (metformin, 
sulfonylureas, and insulin). The pressing need, therefore, 
is to ensure that these basic medicines are available 
throughout sub-Saharan Africa and that clinicians are 
well educated about the ability to treat diabetes with 
simple agents (panel 1).
For type 1 diabetes, the essential therapy is insulin. 
Unfortunately, insulin and other components of care are 
often either unavailable in health-care systems or 
unaffordable to patients. These issues have been 
extensively reviewed elsewhere60,149 and are summarised 
in figure 2. Safe insulin storage is also a problem for 
many families who do not have access to refrigeration 
and so use clay pots for evaporative cooling. 
Encouragingly, evidence indicates that this method is 
effective in reducing storage temperatures towards 
standard room temperature of 20–25°C.150 In addition to 
treating the disease, health-care providers need to 
recognise that the emotional impact on young people 
with type 1 diabetes and their families is often severe, 
especially in countries with relatively low health literacy.151 
Knowledge can help to mitigate this burden, and, given 
the complexity involved in the management of type 1 
diabetes, diabetes education of young patients, their 
families, and health professionals—tailored to culture, 
language, and education or knowledge levels—is critical 
to achieving good outcomes. Several non-governmental 
initiatives exist to provide care for people with type 1 
diabetes in sub-Saharan Africa (appendix 1).
We discuss management of gestational diabetes in 
panel 4.
Management of coexisting risk factors
Overall, cardiovascular disease risk is logically addressed 
by treating overall risk rather than by focusing on 
hyperglycaemia alone.152 This approach presents 
challenges, but the Steno-2 study153 was a striking 
demonstration of the benefits of multifactorial 
intervention in type 2 diabetes. Wherever possible, 
people with diabetes should have regular assessments 
for all risk factors of cardiovascular disease. However, 
studies in sub-Saharan Africa have shown the difficulties 
of such concomitant services. For example, in a slum in 
Nairobi, Kenya, Werner and colleagues154 found that 
only 3·4% of people attended cardiovascular risk clinics 
on a regular basis during 34 months of follow-up. 
Adherence to recommended practice among medical 
professionals is also low, with many doctors in a 
cardiovascular risk clinic failing to follow guidelines for 
concomitant assessment of cardiovascular risk.155 
Additionally, the guidelines for risk evaluation and 
reduction in sub-Saharan Africa are inconsistent, often 
focusing on single risk factors, and are generally 
adaptations of guidelines from other settings.156 More 
evidence from local settings is urgently needed to feed 
into local guidelines.
Although this Commission focuses on diabetes and total 
cardiovascular disease risk, we would be remiss if we did 
not mention that the reduction of cardiovascular disease in 
sub-Saharan Africa requires a concerted effort to reduce 
hypertension, given the high prevalence of hypertension 
in the region. A 2014 systematic review157 of 33 surveys 
involving more than 110 000 participants in sub-Saharan 
Africa found a pooled prevalence of hypertension of 30%, 
but only 27% of people with hypertension were aware of 
their status before the surveys, only 18% were on treatment, 
and only 7% had acceptably controlled blood pressure. In 
fact, the World Heart Federation158 puts both tobacco and 
blood pressure control in third place in its nine steps to 
reduce global burden of cardiovascular disease and does 
not mention control of hyperglycaemia. However, given 
that diabetes and hypertension often co-occur and interact 
synergistically to increase cardiovascular risk, the burden 
of diabetes is likely to increase in sub-Saharan Africa, and 
the adverse effects of diabetes go beyond those of 
cardiovascular disease, diabetes must be considered an 
important risk factor.
Monitoring and managing complications of diabetes
In view of the huge costs involved in managing the 
complications of diabetes, and the increasing burden of 
diabetes, strategies to prevent complications are 
desperately needed in sub-Saharan Africa. Adequate 
management of hyperglycaemia and other risk factors, 
and regular assessment for early evidence of 
complications, are the cornerstones of successful 
strategies to prevent microvascular and macrovascular 
complications. Diabetes registries have been highly 
successful platforms to drive improved outcomes in 
these regards in HICs, but issues with availability of 
technology and other necessary infrastructure mean that 
such registries are largely absent in sub-Saharan Africa.83
Figure 2: Provision of care for children with type 1 diabetes in 20 African and 14 European countries
Percentages of study countries providing 12 key components of diabetes care are shown. Data are from a 
subanalysis of data from the 2015 study by Ogle and colleagues.60
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The availability of management strategies to prevent 
progression or treat complications of diabetes is 
generally poor in sub-Saharan Africa.  Challenges in 
prevention and management of diabetic retinopathy and 
nephropathy illustrate the issues in the region. 
Prevention and management of diabetic retinopathy 
requires both good glycaemic control and timely 
detection and treatment (with photocoagulation) of 
early-stage, sight-threatening retinal changes. However, 
there are insufficient numbers of ophthalmologists 
(about 1 per 1 000 000 population) or opticians in the 
region to perform opportunistic screening for diabetic 
eye disease.159,160 Non-physician cadres, such as 
ophthalmic clinical officers, receive relatively little 
training in retinal disease, and eye services are 
overwhelmed by other conditions.161 Use of mobile 
digital photography with telemedicine links is a potential 
solution to deliver cost-effective, accessible screening to 
rural and remote populations and, given that fundus 
cameras remain prohibitively expensive (cost in the 
region of US$15 000), validation studies are being done 
for several portable fundus cameras.162,163 A simple risk 
score could be an attractive alternative to screening by 
retinal fundus photography to identify those who are 
more likely to be diagnosed with retinopathy (or any 
other major complications) for transfer to screening and 
treatment hubs. However, less than 30% of countries 
have treatment facilities for retinal photocoagulation.83
The prognosis of diabetic nephropathy in populations 
in HICs has greatly improved over recent decades because 
of primary prevention (good glucose and blood pressure 
control) and secondary prevention (regular screening for 
proteinuria and treatment with an angiotensin-converting 
enzyme inhibitor after the onset of proteinuria). 
Furthermore, dialysis and renal transplantation have 
greatly extended the prognosis of patients with end-stage 
disease.153 Unfortunately, many patients with diabetic 
nephropathy in sub-Saharan Africa might not have access 
to such treatments and often progress to end-stage renal 
disease.100,164 Additionally, many parts of sub-Saharan 
Africa have no nephrologists at all (Kenya has one per 
2 million population and South Africa has just over 
one per million),101 and dialysis is unaffordable to many 
patients.104 See the appendix 1 for examples of successful 
initiatives in sub-Saharan Africa for diabetic retinopathy 
and diabetic foot disease.
Screening and prevention of type 2 diabetes
The Commission’s consensus is that the best way to 
manage the diabetes epidemic facing sub-Saharan 
Africa is to prevent the change in dietary habits and 
decline in physical activity leading to overweight and 
obesity that are pervasive across the region. The social, 
economic, cultural, and political elements that are 
needed to ensure prevention of these changes are far 
beyond the remit of this Commission, however, and 
readers are referred to other extensive literature on this 
subject—for example, as summarised in The Lancet 
Physical Activity Series.165
Evidence indicates that screening for diabetes in HICs is 
not beneficial in terms of effect on long-term outcomes.166 
Additionally, no evidence from LMICs suggests that 
screening would be a valuable approach to successfully 
identify and manage people with diabetes or 
hypertension.167 Nevertheless, given the huge number of 
people in sub-Saharan Africa who have diabetes and go 
undiagnosed, many academics and policy makers 
maintain that targeted screening should be done to enable 
earlier identification and treatment.168 Whether such 
targeted screening will work in practice in LMICs, the risk 
scores that would be effective for selecting patients to 
screen, what level of health system infrastructure is 
needed to enable it, and the cost-to-benefits ratios of 
instigating such screening are currently unknown. 
Research is urgently needed to answer these questions 
before putting in place potentially costly screening 
programmes. It has also been suggested that platforms 
for detection of communicable diseases could be co-opted 
to screen for diabetes and cardiovascular risk factors. 
Again, however, there is no evidence that such platforms 
would be a cost-effective method for improving outcomes, 
and research in this area is needed.52
The next steps
The factors limiting access to prevention and management 
options for diabetes, its associated cardiovascular risk 
factors, and long-term complications in sub-Saharan 
Africa are similar. These factors are poor understanding 
of diabetes and its complications among health-care 
professionals and patients; delays in seeking medical 
attention and in patient referral for specialist care; poor 
control of glycaemia and other risk factors; inability of 
patients to afford treatment or transport to attend 
treatment facilities; and, in some cases, a preference by 
patients for alternative traditional therapies.
Thus far, we have illustrated the difficulties in provision 
of good care for patients with diabetes in sub-Saharan 
Africa. We have also given some examples of successful 
strategies in HICs, although whether these strategies are 
transferable to sub-Saharan Africa requires further 
research. Additionally, diabetes affects multiple 
physiological systems and interacts with many other 
diseases to increase the risk of adverse outcomes for a 
patient. Therefore, a broad-based, health-system-
improvement strategy will clearly be central to improving 
outcomes in diabetes. In the following sections of the 
report, we move from clinical considerations to 
considering the health-system approaches that are 
necessary to support clinical aims.
Health-system responses to diabetes in 
sub-Saharan Africa
Although health systems are crucial in a successful 
response to diabetes, most research on diabetes in 
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sub-Saharan Africa has focused on epidemiology and 
clinical presentation, with a few studies83,169 exploring 
health systems, although these were limited in scale 
and scope. We reviewed published studies and analyses 
of surveys to explore health-system responses to the 
increasing burden of diabetes in sub-Saharan Africa. 
We used an established health-systems framework to 
guide our analysis, and we systematically examined the 
response to diabetes with regard to the key health-
system functions of organisation and governance, 
financing, resource management, and service delivery.170
Organisation and governance of diabetes in 
health systems in sub-Saharan Africa
The state capacity, organisational and governance 
structures, and institutional strength of health systems 
vary across sub-Saharan Africa. In 2010, 42 countries in 
the WHO African region reported having a unit or 
department within their ministries of health with 
responsibility for NCDs,171 but just seven countries had 
a national operational policy, strategy, or plan for 
diabetes. This situation has ostensibly improved, and, 
in 2015, the WHO report83 on assessing national 
capacity to address and respond to NCDs—where 
35 (75%) of 47 countries in the WHO African region 
responded to the survey—stated that 100% of countries 
in the WHO African region that responded to the 
survey reported having a unit, branch, or department in 
their ministry of health that was responsible for NCDs. 
Additionally, 72% of countries had an operational 
policy, strategy, or action plan that integrated NCDs and 
their risk factors. However, looking specifically at sub-
Saharan Africa,171,172 only 20 countries reported having 
an operational policy, strategy, or action plan for 
diabetes (nine countries did not and the remainder did 
not respond).
In 2010, the availability and the stage of implementation 
of guidelines, protocols, or standards for diabetes 
management varied across countries. Just four countries 
in the WHO African region that responded to the WHO 
report83 had guidelines, protocols, or standards that were 
fully implemented. Although data are not available 
specifically for sub-Saharan Africa, in 2015, globally, 
75% of countries reported guidelines for dealing with 
diabetes,83 so the situation has probably improved in the 
region since 2010.
Financing of health care in sub-Saharan Africa
In 2014, total health expenditure in sub-Saharan Africa as 
a proportion of GDP averaged 5·5% (ranging from 6·4% 
in the 23 LICs, 6·0% in the three countries of lower-
middle income, 5·4% in the five countries of upper-
middle income, and 3·3% in one HIC).7,12 19 countries 
were below the Chatham House recommendation of 
5% of GDP spent on health.173 In the same year, average 
public spending on health accounted for 42·6% of total 
health expenditure.7,12 External funding ranged from 
64·9% in The Gambia to 0·3% in Equatorial Guinea, 
with an average of 11·2%.
In 2001, African nations adopted the Abuja 
Declaration, pledging to allocate at least 15% of their 
national annual budgets to health spending.174 Yet, 
by 2013, only seven countries in sub-Saharan Africa—
Central African Republic, Ethiopia, Malawi, Rwanda, 
Swaziland, Togo, and Uganda—had reached that 
target.12 In 2014, the average out-of-pocket expenditure 
as a percentage of total expenditure on health 
was 34·5%, ranging from 73·5% in Sierra Leone 
to 2·3% in Seychelles.7,12,172 In seven countries, out-of-
pocket expenditure comprised more than 50% of the 
total health expenditure (down from 12 countries 
in 2010). Although unknown, we assume out-of-pocket 
expenditures to be high for diabetes and often 
prohibitive, producing financial barriers to access and 
leading many individuals with diabetes to not seek care 
(and thus avoiding short-term treatment costs but 
potentially accumulating larger health deficits, leading 
to even higher long-term direct costs through more 
severe sequelae due to target organ damage, such as 
amputations, blindness, stroke, or kidney failure, in 
addition to decreased lifespan). Comorbidities and 
sequelae in many instances result in catastrophic or 
impoverishing health-care expenditures, sinking many 
patients and their families beneath the poverty line. For 
example, in a multicountry study175 that included 
Tanzania, India, China, and Argentina, catastrophic 
health spending related to cardiovascular events was 
reported in 92% of low-income population groups, with 
distress financing in 4–12% of low-income groups.
Low levels of public funding, low income levels, and 
high out-of-pocket expenditures have adversely affected 
the uptake and provision of care for patients with 
diabetes, increasing the likelihood of long-term 
complications. For example, in Malawi in 2012, families 
spent 22% of their monthly per-capita budget on out-of-
pocket expenditures related to NCDs.176,177 For patients 
with type 1 diabetes, high out-of-pocket expenditures and 
the unaffordability of care have grave consequences; 
these patients have a high mortality because regular 
insulin injections are not always affordable.26,149
To increase health financing for NCDs, several 
countries, such as Cameroon, Botswana, and Seychelles, 
have introduced earmarked taxation to influence health 
behaviours, with revenues channelled to health 
promotion activities. Others have launched reforms to 
increase public funding for health systems and to achieve 
universal health coverage, but large informal sectors 
hinder effective tax collection to invest in health systems. 
Against this backdrop and the competing demands of a 
high burden of infectious diseases and other diseases 
associated with poverty, it is highly unlikely that health 
systems in sub-Saharan Africa will have adequate 
financing to deal with an epidemic of diabetes and its 
consequences.
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Resource management in health systems for 
tackling diabetes in sub-Saharan Africa
Sub-Saharan Africa has an acute shortage of health-care 
professionals; the WHO African Region accounts for 
25% of the current global health workforce shortage, 
expected to rise to 34% by 2035 as a result of population 
growth in Africa.178 The shortage of health workers, 
exacerbated by emigration,179 has constrained achieve-
ment of the Millennium Development Goals in sub-
Saharan Africa.180
There is shortage of medical graduates (more than half 
of the countries in sub-Saharan Africa have only one 
medical school, and 11 countries have no medical 
school178,179) and nurses, whose level of training and skills 
vary greatly across countries.181 More than half of countries 
in sub-Saharan Africa have a category of non-physician 
clinician (providers who complete an average of about 
3 years of clinical training after secondary education),181 
and many countries, such as Ethiopia and Malawi, have 
successfully used community health workers to scale up 
HIV, tuberculosis, malaria, and other essential services.182,183 
These strategies should be considered for use in managing 
diabetes and other cardiovascular disease risk factors.
The scarcity of human resources affects the capacity of 
health systems, and their readiness to manage diabetes is 
revealed by examining WHO Service Availability and 
Readiness Assessment (SARA)184 surveys for ten  countries 
in sub-Saharan Africa (Benin 2013, Burkina Faso 2012 
and 2014, Democratic Republic of the Congo 2014, 
Kenya 2013, Mauritania 2013, Togo 2012, Uganda 2013, 
Tanzania 2012, Sierra Leone 2012, and Zambia 2010). 
WHO SARA surveys are designed to assess the national 
capacity of health systems in countries and can be applied 
to assess prevention and control of NCDs by measuring 
the availability of diagnostic tools, essential medications, 
and trained staff at the health-care-facility level by use of 
tracer conditions, such as diabetes and cardiovascular 
disease.184 The methodology for the surveys is described 
elsewhere.184 Findings from the country-level SARA 
reports indicate that major gaps exist in front-line service 
delivery. In the surveyed countries, less than half of 
facilities offered diabetes management. Of the facilities 
not offering diabetes services at the time of the survey, 
just 40–60% demonstrated service readiness (table 3).
With the exception of Uganda, only about a third of 
facilities offering diabetes services had guidelines for 
treatment, and one-third or fewer had at least one 
diabetes-trained member of staff. The discrepancy 
between the number of trained staff and availability of 
diagnostic supplies and drugs is concerning because it 
is not clear how supplies and drugs are being used in 
the absence of staff with formal training in diabetes 
care. The availability of blood glucose testing ranged 
from 14% in Burkina Faso (similar to what Beran and 
colleagues185 found in Mali and Mozambique) to 80% in 
Uganda, although only 31% of Uganda sites reported 
the availability of diabetes-trained staff.
SARA survey data add to the findings of a literature 
review (see below) to reveal the consequences of under-
funded and weak health systems and years of suboptimal 
investments in human resources,186 which have led to large 
resource gaps for diabetes care in sub-Saharan Africa.
Availability and access to medicines for diabetes 
in sub-Saharan Africa
According to WHO, essential medicines for diabetes 
(metformin, glibenclamide, and insulin) were not available 
in all sub-Saharan African countries in 2010 (figure 3): of 
the 45 countries surveyed, metformin was available in 
29 countries; glibenclamide was available in 35 countries; 
insulin was available in 32 countries; and aspirin, used for 
primary prevention of cardiovascular disease in patients 
with diabetes, was available in 41 countries that 
responded.172 In 2015, however, WHO found that, of the 
countries in the WHO African region, 51% had availability 
of metformin, 40% had availability of insulin, and 71% had 
availability of aspirin in the public sector.83
The WHO Global Action Plan for the Prevention and 
Control of NCDs 2013–20 has a target of 80% availability 
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Figure 3: General availability of diabetes medicines in the public health 
sector in 45 sub-Saharan African countries
Data are from the WHO Global Health Observatory data repository on 
non-communicable-disease-related medicines and are for 2010. Data by country 
can be obtained from reference 172.
Insulin (%) Metformin (%) Glibenclamide (%)
Hospital 48% (28–100) 49% (21–87) 65% (39–94)
Health centre 17% (0–95) 32% (8–64) 31% (11–100)
Primary health centre 12% (1–34) 31% (2–65) 48% (4–68)
Dispensary 13% (0–24) 13% (0–48) 13% (0–43)
Urban 7% (4–43) 19% (6–75) 30% (8–71)
Rural 12% (2–51) 23% (1–42) 28% (3–72)
Public 3% (2–35) 7% (1–42) 16% (3–78)
Private 11% (5–46) 33% (4–86) 39% (7–85)
Overall 13% (3–39) 22% (2–57) 32% (5–70)
Data are median (range) and are from WHO Service Availability and Readiness Assessment surveys.184 Included 
countries are Benin (2013), Burkina Faso (2012), Democratic Republic of the Congo (2014), Kenya (2013), Mauritania 
(2013), Sierra Leone (2012), Tanzania (2012), Uganda (2013), and Zambia (2010).
Table 4: Availability of insulin, metformin, and glibenclamide in nine sub-Saharan countries
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for affordable basic technologies and essential 
medicines, including generic drugs, required to treat 
major NCDs in both public and private facilities.187 
Although reaching this target is essential if sub-Saharan 
African countries are to meet the target of a 25% relative 
reduction in premature mortality from NCDs by 2025, 
studies reveal access challenges due to a lack of 
availability and affordability of medications. For 
example, studies reveal 75% median availability (actual 
stocking) of insulin in the public sector (five countries) 
and 46% in the private sector (six countries),149 and 
challenges associated with the availability and 
affordability of oral medicines.139,188–190 In 2004–13, 
only eight (16·7%) countries in sub-Saharan Africa 
bought insulin every year and 14 (29·2%) countries did 
not buy insulin at all during this period.191
WHO SARA survey reports from 2010–13 on the 
nationwide availability of insulin, metformin, and 
glibenclamide for nine sub-Saharan African countries 
showed the median availability of insulin to be 13% 
(range 3–39; table 4). Insulin availability was generally 
decreased at lower levels of the health system (ie, primary 
care), with availability of 12% (2–51) in rural areas and 
7% (4–43) in urban areas, and 11% (5–46) in the private 
sector and 3% (2–35) in the public sector. The overall 
median availability of metformin was 22% (2–57), which 
also showed decreased availability at lower levels of the 
health system and increased availability in rural areas 
and the private sector. The findings were similar for 
glibenclamide, although glibenclamide was slightly more 
available in urban areas than in rural areas (table 4).184
Despite these findings, these medications are not 
expensive. Management Sciences for Health (MSH) 
provide international reference prices for many 
medicines.192 The prices quoted by MSH are from 
tenders of ministries of health and represent medicine 
prices without any add-on costs at the point of entry to a 
given country. Analysis of data from 1996 to 2013 
suggests that the median price for insulin (a 10 mL, 
100 IU/mL vial) in sub-Saharan Africa (eight countries) 
was US$7·15 (range $1·52–17·58) at constant 2015 
prices.193 Additionally, the median prices were $0·018 
($0·002–3·304) for metformin (500 mg, ten countries); 
$0·023 ($0·012–0·060) for gliclazide (80 mg, four 
countries), as representative of a cheap sulfonylurea that 
is suitable for patients older than 60 years; and $0·004 
($0·0004–0·032) for glibenclamide (5 mg, 13 countries).192 
The treatment costs, using defined daily dose,194 are 
shown in table 5. These data show that treatment of 
diabetes with insulin presents a significantly higher cost 
to individuals than treatment with oral drugs. In addition 
to purchase price, medicine costs are affected by the cost 
of delivering medicines and mark-ups along the supply 
chain.149 The prices shown in table 5 do not take into 
account any mark-ups, such as value-added sales tax, 
local taxes, international purchasing verification tax, 
insurance, defence levy, overhead mark-ups, bank fees, 
fees for import declaration forms and port clearance, 
importer margin, handling costs, wholesale mark-ups, 
retail mark-ups, health facility mark-ups, dispensing 
charges, or other mark-ups within the system. The 
prices also do not reflect the additional costs of ensuring 
health-care personnel are adequately trained to prescribe 
the treatments. Although data for these mark-ups are 
scarce, particularly for insulin, the additional costs of 
these taxes and levies for the other medicines have been 
found to range from 18·4% to 94·4% of the final retail 
price of the drug.193
These add-on costs, as well as subsidies within health 
systems, mean that many factors affect the price and 
affordability of insulin and that the total cost of insulin 
therapy can vary from 0·2% of total GDP in South Africa 
to 13·4% in Malawi.193 For example, data from four 
studies done in three African countries at different 
times suggested that medicine prices increased in 
Mozambique (2003) and Mali (2004) between the central 
government purchase price and the price paid by health 
facilities to recuperate storage and transportation costs. 185 
An increase in prices was not observed in Zambia and 
Mozambique (2009). In Mozambique and Zambia, the 
difference between the facility purchase price and the 
patient purchase price was subsidised, whereas in Mali, 
there was an additional mark-up, such that there was a 
47% increase between the government purchase price 
and the patient purchase price. 
To present different prices of insulin, we combined 
different data sources to show the median price (at 
2015 prices) at different levels of the health system 
(figure 4).193 These data show that, by comparing the 
MSH prices with those obtained by different ministries 
of health, many countries in sub-Saharan Africa were 
purchasing insulin at the best possible price, although 
there were some outliers. In some countries, insulin was 
provided free-of-charge or subsidised to patients in the 
public sector, whereas, in other countries, the prices were 
higher but still low compared with prices in the private 
sector. The prices shown in figure 4 are not affordable to 
individuals in some countries—for example, at the upper 
end of the scale, a 10 mL vial of insulin (100 IU/mL) cost 
Annual 
costs (US$)
Cost per 
day (US$)
Percentage of income 
per day
US$1·90* US$3·10†
Insulin 104·40 0·29 15·1% 9·2%
Metformin 26·94 0·07 3·9% 2·4%
Gliclazide 16·96 0·05 2·4% 1·5%
Glibenclamide 3·17 0·01 0·5% 0·3%
Data are median. Data come from Management Sciences for Health and authors’ 
calculations. Costs were calculated using defined daily dose.194 *US$1·90 is the 
global poverty line, as of October 2015.4 †Used as poverty head count ratio.195 
Table 5: Treatment costs for diabetes medicines and their percentage of 
two different daily incomes
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US$10·88 in 2004 in the public sector in Mali or 
$50·57 in 2015 in the private sector in Ethiopia.193
Data from WHO/Health Action International (HAI)190 
suggest that, in some sub-Saharan African countries, 
people have to pay between 0·9 and 6·7 days of wages to 
afford 1 month of their diabetes treatment (figure 5). 
Affordability is defined by WHO/HAI as the lowest-paid 
government worker paying only 1 day’s wage for 
treatment. Hence, according to the data shown in 
figure 5, only glibenclamide in Ethiopia is affordable.
However, in sub-Saharan Africa many individuals do 
not work in the formal sector, and hence measuring 
affordability in terms of the wage of the lowest-paid 
government worker is problematic, especially because 
most people live on less than $1·90–3·10 per day.4 A 
comparison of the annual costs of diabetes medicines 
(table 5) and the daily costs of the different diabetes 
treatments, using different poverty thresholds of daily 
income, shows that daily drug costs (ministry of health 
purchase prices and not retail price) represent 
0·5–15·1% of income for someone with diabetes living 
on $1·90 per day.
Health service delivery for diabetes in 
sub-Saharan Africa
Analysis of Service Delivery Indicator surveys
To identify service delivery gaps in diabetes care we 
analysed data from Service Delivery Indicator (SDI) 
surveys done in four sub-Saharan African countries by 
the World Bank, in cooperation with the African 
Economic Research Consortium and the African 
Development Bank.138 The SDI surveys include data at 
the level of the health facility on expenditures, provider 
effort (absence rate, caseload per provider), provider 
knowledge and ability (diagnostic accuracy, adherence to 
clinical guidelines, and management of maternal and 
neonatal complications), and inputs (availability of 
supplies, equipment, and drugs). Diagnostic accuracy is 
measured through patient case simulations (vignettes) 
for seven tracer conditions: malaria with anaemia, 
diarrhoea with severe dehydration, pneumonia, diabetes, 
pulmonary tuberculosis, postpartum haemorrhage, and 
neonatal asphyxia.
The SDI surveys are complementary to and build on 
surveys (eg, WHO SARA surveys) that focus on the 
availability of resources and health system readiness for 
service provision, including for NCDs. Our analysis of 
SDI surveys broadens and deepens our understanding of 
service delivery and the quality of diabetes care in sub-
Saharan Africa by providing insights into the knowledge, 
ability, and effort of providers (technical quality), and the 
availability of important inputs, such as drugs, 
equipment, and infrastructure (structural quality; see 
appendix 1 for additional information and methods).
We investigated the four publicly available SDI 
surveys: Kenya (2012), Nigeria (2013), Tanzania (2014), 
and Uganda (2013). When presented with vignettes, less 
than 53% of the sampled providers in all countries 
could accurately diagnose diabetes, with the exception 
of Kenya where 81% of providers gave the correct 
diagnosis (weighted results; figure 6A). Conversely, in 
all countries except Nigeria, more than 80% of providers 
could diagnose tuberculosis, with the proportion as 
high as 98% in Kenya and 92% in Tanzania (figure 6A). 
Only 4% of the sample could correctly diagnose all 
seven conditions. The proportion of providers able to 
identify all seven conditions was highest in Kenya, 
where almost 17% of the surveyed providers correctly 
diagnosed all conditions presented during the patient 
simulation.
Although the average clinical guideline score—
indicating the degree of adherence to diabetes clinical 
guidelines—was less than 30% in all countries, we 
observed a wide range of performance scores within 
countries, with some providers performing all necessary 
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Figure 4: Price per vial of insulin at different levels of the health system
Prices (standardised to 2015 US$) of a vial of human insulin (10 mL, 100 IU/mL 
vial) reported by 18 sub-Saharan-African countries. Prices differed in both the 
public and private sectors depending on whether the vials were purchased from 
primary care centres, retail pharmacies, or hospitals. Procurement prices 
obtained by MSH are also shown. Data are from ACCISS Study Insulin Price 
Profile 2016.193 MSH=Management Sciences for Health. 
Ethiopia
Kenya
Nigeria
Tanzania
0 1 2 3 4 5 6 7 8
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Figure 5: Affordability of oral drugs for diabetes care in day’s wages for the 
lowest-paid government worker in four countries in sub-Saharan Africa
Affordability was measured in the number of day’s wages that the lowest-paid 
government worker needed to pay for 1 month of treatment of metformin or 
glibenclamide in 2004. Data are from the WHO/Health Action International 
database of medicine prices.190
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tasks in the domains of the score (symptom, patient, 
history, and physical examination; figure 6B).
More than half of providers who correctly diagnosed 
diabetes could not prescribe the appropriate treatment, 
with the exception of Tanzania, where 89% of the 
providers who correctly diagnosed diabetes prescribed 
oral hypoglycaemics (figure 6C). In addition, 77% of 
providers in Kenya who correctly diagnosed diabetes 
indicated that they would refer to higher-level facilities. 
In other countries, this share ranged from 34% to 47% of 
providers. Whether this pattern of referral is due to a lack 
of knowledge or confidence in applying the knowledge is 
not known. However, as the number of diagnosed 
patients increases, referring the majority to higher-level 
facilities is unlikely to be a sustainable option.
To investigate the association between provider and 
facility characteristics and the provider’s ability to correctly 
diagnose diabetes, we did a logistic regression analysis. 
Table 6 shows a summary of the analytic sample of 
provider and facility characteristics in these countries. The 
total sample consisted of 6146 providers, with the largest 
number of providers coming from Nigeria. With the 
exception of Tanzania, nurses, midwives, and community 
health workers represented more than half of the sampled 
providers. In Tanzania, 75% of the sample consisted of 
physicians and medical or clinical officers. In Nigeria, 
physicians represented only 10% of the sample, whereas 
nurses, midwives, and community health workers 
represented 82% of the sample (predominantly 
community health workers). In Kenya, Nigeria, and 
Uganda, most of the sampled providers were female.
The facility statistics in table 6 show that most providers 
in all countries were employed at lower-level facilities 
(eg, dispensaries or health centres) and, except for 
Tanzania, were primarily located in rural areas. Generally, 
providers worked at facilities with a high equipment 
index, suggesting that they had access to a thermometer, 
adult weighing scale, sphygmomanometer, and 
stethoscope. In Nigeria and Uganda, however, more than 
a third of providers did not have access to all four pieces 
of equipment.
Table 7 shows the logistic regression results of the factors 
associated with a provider’s ability to diagnose diabetes. 
Female providers had significantly lower odds than male 
providers of correctly diagnosing diabetes in Kenya (odds 
ratio [OR] 0·58, 95% CI 0·35–0·98) and Nigeria (0·73, 
0·61–0·86), but we cannot explain the reasons behind this 
difference. Compared with the highest cadre category 
(physicians, medical officers, and clinical officers), lower 
cadres had significantly lower odds of diagnosing diabetes 
in most countries. This result suggests that there is room 
for improvement in training of lower cadres of health 
providers in diagnosing diabetes.
It is encouraging that geographical location was not a 
significant predictor in any of the four countries, with 
providers in rural areas not having statistically lower odds 
of diagnosing diabetes than those in urban areas. We did 
26
64
79
8183
94
98
10
28 2625
29
43
33
70
55
34
51 52
43
76
49
54
88
67
58
92
83
Pr
ov
id
er
s c
or
re
ct
ly
 d
ia
gn
os
in
g 
(%
)
Di
ab
et
es
 cl
in
ica
l g
ui
de
lin
e 
sc
or
e 
(%
)
50
36
89
41
6
35
11
18
77
34
39
47
Kenya Nigeria Tanzania Uganda
Oral hypoglycaemics
Insulin only when oral hypoglycaemics are not effective
Follow-up at a specialist diabetes clinic or higher-level facility
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
Pr
ov
id
er
s c
or
re
ct
ly
 d
ia
gn
os
in
g 
di
ab
et
es
 (%
)
A
C
B
Diabetes
Pneumonia
Post-partum haemorrhage
Diarrhoea
Malaria
Neonatal asphyxia
Tuberculosis
Figure 6: Measures of health service delivery for diabetes in sub-Saharan Africa
Data are from Service Delivery Indicator surveys from four countries: Kenya (2012), Nigeria (2013), Tanzania 
(2014), and Uganda (2013). The number of providers in each country is shown in table 6. For weighting of the 
data, see reference 196. (A) Share of providers correctly diagnosing each patient simulation vignette by country. 
(B) Box plot of clinical guideline scores by country; boxes are shown as median and IQR; the dots show outliers and 
the red line indicates 50%. (C) Treatment prescribed by providers who correctly diagnosed diabetes.
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not find a statistically significant association between the 
ability of providers to diagnose diabetes and whether the 
facility was public in all countries studied. Interestingly, in 
Kenya and Nigeria, a higher equipment index (table 6) was 
found to significantly increase the odds of correctly 
diagnosing diabetes. Although the availability of a 
glucometer was not generally recorded in the SDI surveys, 
good availability of the other equipment might be 
reflective of the availability of a glucometer and hence an 
increased ability to diagnose diabetes. As mentioned 
earlier, the variation in the equipment index was quite low, 
with most providers having access to the basic equipment 
(particularly in Kenya); thus, the significant ORs suggest 
that ensuring universal availability of basic equipment 
could substantially improve diagnostic accuracy.
Table 8 shows the ordinary least squares regression 
results of the factors associated with higher clinical 
guideline scores. The dependent variable was the log-
transformed clinical guideline score. The results were 
consistent with the findings for diagnostic accuracy 
(table 7). Providers in lower cadres were less likely to 
have high clinical guideline scores than providers in 
higher cadres. Nurses, midwives, and community health 
workers were found to have 10–45% lower clinical 
guideline scores than physicians and medical and clinical 
officers. In Nigeria and Tanzania, providers at district 
hospitals were found to have a 45% and 42%, respectively, 
higher clinical guideline score than providers at the 
lowest level facilities. The equipment index was also 
positively associated with the clinical guideline score in 
Nigeria and Uganda.
The analyses of service delivery indicators suggest that, 
in the countries studied, there is low readiness across all 
levels of care and cadres of health professionals in 
management of diabetes in terms of correct diagnosis, 
adherence to guidelines, and provision of appropriate 
treatment. This finding suggests that lower levels of care 
are unprepared for diabetes diagnosis and treatment, 
which has implications for development and scaling up of 
community-based or primary health care-based diabetes 
management programmes in sub-Saharan Africa.
Implications of health system responsiveness to 
diabetes in sub-Saharan Africa
The findings from WHO SARA surveys and World Bank 
SDI surveys revealed that health systems in sub-Saharan 
Africa are unprepared for delivery of effective health 
services for patients with diabetes. However, a 
comprehensive understanding of how resource and 
service gaps in health systems affect demand, and how 
the interaction of supply-side gaps and demand-side 
dynamics translate into unmet need in sub-Saharan 
Africa, is constrained by scarce data. In the next section, 
we analyse surveys of 12 sub-Saharan African countries 
to examine the nature and extent of unmet need at each 
crucial stage of the diabetes care process.
Analysis of unmet need and the cascade of care 
for diabetes in sub-Saharan Africa
One innovative analytical approach to assess health 
system performance is the construction of a cascade of 
care with a tracer condition. Cascade-of-care analysis 
involves quantitative depiction of the step-wise care for 
the population affected by a disease of interest, 
including screening, diagnosis, linkage to treatment 
programmes, adherence to treatment, and finally 
achievement and maintenance of control. This analysis 
depicts the dynamics between demand and health 
system responses at each step of the care continuum 
and provides the opportunity to identify areas of unmet 
need and where attrition in care occurs.11
Cascade-of-care analysis has been used to monitor 
progress towards coverage goals for populations affected 
by HIV/AIDS.197,198 In the USA, 2007–12 data from the 
National Health and Nutrition Examination Survey 
(NHANES) have been used to construct a cascade of care 
for diabetes to show that nearly a third of patients with 
diabetes are unaware of their diagnosis, and that those 
who are undiagnosed are less likely than those with a 
diagnosis to achieve health targets for multiple chronic 
diseases.199
We used individual-level data from population-based 
surveys done between 2005 and 2013 in 12 sub-Saharan 
African countries to assess unmet need for care and the 
care cascade for diabetes. WHO STEPS survey data were 
Kenya 
(n=526)
Nigeria 
(n=4388)
Tanzania 
(n=498)
Uganda 
(n=684)
Provider characteristics
Cadre
Physicians/medical officers 241 (46%) 456 (10%) 371 (75%) 146 (21%)
Nurses/midwives 22 (4%) 859 (20%) 127 (25%) 520 (76%)
Community health workers 240 (46%) 2705 (62%) NA NA
Other 23 (4%) 368 (8%) NA 18 (3%)
Provider is female 320 (61%) 2721 (62%) 199 (40%) 417 (61%)
Provider performance
Correctly diagnosed diabetes 431 (82%) 1492 (34%) 194 (39%) 322 (47%)
Clinical guideline score* 0·28 (0·16) 0·20 (0·17) 0·24 (0·14) 0·12 (0·09)
Facility characteristics
Facility type
Dispensary 138 (26%) 299 (7%) 306 (62%) 382 (56%)
Health centre 290 (55%) 3285 (75%) 124 (25%) 284 (41%)
District hospital 98 (19%) 804 (18%) 68 (14%) 18 (3%)
Rural 363 (69%) 2413 (55%) 249 (50%) 534 (78%)
Public 331 (63%) 4212 (96%) 339 (68%) 465 (68%)
Equipment index† 0·97 (0·10) 0·77 (0·32) 0·95 (0·13) 0·79 (0·27)
Data are n (%) or mean (SD). The total sample consisted of 6146 providers, of whom 6096 were analysed. NA=not 
applicable.*The clinical guideline score was calculated as the share of all tasks expected to be done (eg, patient history, 
symptoms, physical examination) when a patient presents with diabetes symptoms. †The equipment index was 
calculated as the share of four essential pieces of equipment available and functioning at facilities: 
sphygmomanometer, thermometer, stethoscope, and weighing scale. 
Table 6: Summary statistics of the analytic sample of the Service Delivery Indicator surveys from 
Kenya (2012), Nigeria (2013), Tanzania (2014), and Uganda (2013)
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available for ten countries: Benin, Comoros, Guinea, 
Kenya, Liberia, Mozambique, Seychelles, Tanzania, Togo, 
and Uganda. The STEPS survey is a standardised 
approach to collecting data about cardiovascular NCDs 
from adults aged 25–64 years in WHO member countries. 
Briefly, the STEPS surveys include collection of 
demographic data (step 1); physical measurements such 
as blood pressure and BMI (step 2); and biochemical 
measurements, including fasting plasma glucose 
(step 3).200 Further details about the STEPS instrument 
are provided elsewhere.5 Given that a standardised 
approach is used in all countries, data from the STEPS 
surveys can be used to compare epidemiology and health-
system performance across countries.
We supplemented data from STEPS surveys with 
information from the Demographic and Health Survey 
for Namibia (2013),201 which, similar to STEPS surveys, 
includes both fasting plasma glucose measurements and 
self-reported data about access to diagnosis and treatment 
for diabetes. For South Africa, we used the 2013 South 
Africa Nutrition and Health Examination Survey 
(SANHANES), a nationally representative cross-sectional 
health and nutrition study led by the South African 
Human Sciences Research Council.202 Together, the 
STEPS, Demographic and Health, and SANHANES 
surveys consisted of 38 311 individuals across 12 countries 
over the period of 2005–15. How we pooled individual 
data from different datasets to enable comparability is 
described in the appendix 1. In panel 5 we briefly describe 
the approach used to define diabetes and the method 
used to construct the care cascade. The methods used to 
pool data from different surveys, construct the care 
cascade, and identify unmet need, as well as the 
limitations of that analysis, are described in detail 
elsewhere.11
The diabetes care cascade across all countries is shown 
in figure 7. The first step in the cascade is receipt of a 
diagnostic test, specifically a blood glucose measurement. 
This initial diagnostic test was associated with the 
greatest loss to care in all countries, with an average loss 
to care of 50% (range 23–81). Among the group who self-
reported having received a glucose measurement, the 
cascade shows that, on average, 13% (0–26) of the total 
population with diabetes was then lost to follow-up at the 
stage of being told about their diagnosis by a health-care 
provider (figure 7). Among those who reported 
completing the first two steps in the cascade, an 
additional 20% (5–31) of the total population with 
diabetes was lost to care and follow-up at the stage of 
receiving advice on lifestyle modification. Finally, a 
further 6% (3–10) of the total population with diabetes 
was lost to care between the stages of receiving advice 
and receiving any medication, including oral medication 
or insulin, for diabetes control. Overall, the analysis of 
the data from the 12 countries showed that the average 
percentage of the population with diabetes who 
completed the care cascade was 11%, with a range of 7–33.
The care cascades for three exemplar countries 
(Mozambique, Kenya, and South Africa) are shown in 
the appendix 1. These three countries were chosen as 
examples because they represent three very different 
levels of wealth, as measured by GDP per capita in 2011 
international dollars for the year of the survey 
(Mozambique [2005]: Intl$735, Kenya [2015]: $2818, 
South Africa [2013]: $12 375).
Our analysis shows unmet need at every step of the 
diabetes care continuum, which leaves around 50% of 
patients with diabetes going undiagnosed and further 
substantial dropoffs in care throughout the remainder of 
the cascade. From this analysis, and what is known about 
unmet need in the region, we surmise that for people 
diagnosed with or at risk of diabetes, health systems are 
unable to provide the needed services, with most patients 
not receiving the necessary advice and medication. 
Unmet need and suboptimal care mean that patients will 
probably have delayed presentation to the health system 
and receive advice and medication late in the care 
process. Delayed presentation and treatment have 
adverse effects on health outcomes in diabetes, leading to 
Kenya (n=526) Nigeria (n=4388) Tanzania (n=498) Uganda (n=684)
Provider characteristics
Provider’s age
<30 years Ref Ref Ref Ref
30–59 years 1·73* (1·10–2·74) 0·77* (0·62–0·95) 1·30 (0·66–2·65) 0·83 (0·60–1·15)
>60 years NA 1·99 (0·96–4·13) 1·50 (0·52–4·31) NA
Provider is female 0·58* (0·35–0·98) 0·73† (0·61–0·86) 0·67 (0·43–1·05) 0·85 (0·57–1·26)
Cadre
Physician/ 
medical officer‡ Ref Ref Ref Ref
Nurse/midwife 1·31 (0·48–3·59) 0·68* (0·50–0·94) 0·53* (0·29–0·95) 0·18† (0·11–0·31)
Community 
health worker 0·56 (0·32–1·01) 0·25† (0·18–0·34) NA NA
Other§ 0·64 (0·20–2·01) 0·32† (0·22–0·47) NA 0·19† (0·06–0·64)
Facility characteristics
Facility type
Dispensary Ref Ref Ref Ref
Health centre 0·80 (0·44–1·46) 0·71* (0·50–1·00) 1·64 (0·97–2·76) 2·26† (1·57–3·26)
District hospital 1·21 (0·48–3·06) 1·57* (1·04–2·37) 3·08† (1·53–6·19) 2·45 (0·78–7·67)
Location
Urban Ref Ref Ref Ref
Rural 0·94 (0·52–1·70) 0·84 (0·70–1·00) 0·92 (0·57–1·47) 0·64 (0·39–1·03)
Facility is public 0·68 (0·41–1·15) 1·47 (0·92–2·35) 0·81 (0·49–1·33) 1·32 (0·88–1·98)
Equipment index¶ 8·10† (1·68–39·10) 1·51† (1·12–2·03) 5·70 (0·78–41·77) 2·28 (0·99–5·28)
Data analysed were from Service Delivery Indicator surveys from Kenya (2012), Nigeria (2013), Tanzania (2014), 
and Uganda (2013). Data are odds ratio (95% CI). Binary-dependent variable was equal to 1 if a provider correctly 
diagnosed diabetes during the patient simulation vignette, 0 otherwise. NA=not applicable. *p≤0·05. †p≤0·01. ‡Also 
includes clinical officers. §Includes paraprofessionals and lab technicians. ¶Equipment index was calculated as the share 
of four essential equipment available and functioning at the facilities: sphygmomanometer, thermometer, 
stethoscope, and weighing scale. 
Table 7: Logistic regression results of the determinants of a provider’s ability to diagnose diabetes
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difficulties for patients and their families due to ill health 
and to adverse economic consequences for patients, their 
families, and their countries.
Economic consequences of diabetes in 
sub-Saharan Africa
Economic burden of diabetes to individuals
In addition to ill health and substantial reductions in 
quality of life, diabetes imposes a non-negligible financial 
burden on affected individuals, families, and societies. 
While patients with diabetes face direct costs of illness 
through medical treatment of the disease and its 
comorbidities and sequelae, they also experience income 
losses through reduced productivity and disability, which 
means inability to work in severe cases.
The relatively high prices for necessary health items, 
such as blood glucose strips and insulin, impose a 
considerable financial burden on individuals, as discussed 
in previous sections of this report. Combined with the 
substantial reliance of health systems in sub-Saharan 
Africa on out-of-pocket expenditure, patients with diabetes 
in the region often have only limited access to adequate 
and timely treatment, potentially resulting in an increased 
risk of diabetes-related health complications. Moreover, 
comorbidities and target organ damage due to diabetes 
might cause catastrophic health-care expenditures, 
shifting many patients and their families beneath the 
poverty line.203 Simultaneously, these adverse effects are 
likely to be perpetuated in the absence of adequate social 
security systems; families might attempt to offset such 
catastrophic expenditures by putting children into the 
workforce, thus cutting short their education and reducing 
their future prospects of financial wellbeing.
Measurement of the direct economic burden on 
individuals is complicated by the fact that health 
expenditure for diabetes-related complications is difficult 
to quantify because diabetes might not be the only 
attributable cause. The IDF therefore derives estimates 
for direct costs of diabetes from each country’s total 
health expenditure, applying age-specific and sex-specific 
ratios of average heath expenditure to people with and 
without diabetes. Accordingly, estimated per-patient 
expenditures for diabetes in 2015 in sub-Saharan Africa 
ranged between US$243 and $419,25 although the validity 
of these numbers is unknown because cost ratios were 
based on US data. A 2017 study204 that used a similar 
approach but different cost ratios for LMICs found 
average per-patient costs of $580. Other studies estimated 
direct costs of diabetes per person each year to be $138 in 
Tanzania in 1989–90,205 and $489 in Cameroon in 2001.206 
Although not all of these expenditures are borne by 
individuals directly through out-of-pocket payments, 
increased insurance contributions and taxes can serve to 
further burden individuals.
Indirect costs of illness result from productivity losses of 
workers during their productive years (because costs of 
early mortality are not borne by patients themselves, we do 
not consider this position in this section). These 
productivity losses comprise absenteeism (sick workers 
failing to appear for work), presenteeism (unfit workers 
coming to work but not performing to full capacity), and 
labour-force dropout (panel 6). Notably, whereas in HICs 
productivity losses might be partially or fully offset by 
social security systems (eg, continued pay during sick 
leave, insurance payments in case of permanent disability), 
in sub-Saharan Africa productivity losses are likely to fully 
accrue at the level of the sick individual through foregone 
wages from formal or informal work and reduced 
agricultural yield in the case of subsistence farmers.
Economic burden of diabetes to countries
Evidence about the total economic burden of diabetes to 
societies in sub-Saharan Africa is scarce. Kirigia and 
colleagues215 estimated that the combined direct and 
indirect costs amounted to Intl$25·51 billion (2005 
purchasing power parity) in 2000, but they might not 
have captured the full picture because diabetes-related 
complications were excluded from their analysis. We 
therefore based our evaluation of economic burden to 
countries on a top-down approach used in a study by 
Kenya 
(n=526)
Nigeria 
(n=4438)
Tanzania 
(n=498)
Uganda 
(n=684)
Provider characteristics
Provider’s age
<30 years Ref Ref Ref Ref
30–59 years –0·06 (0·06) –0·11*(0·05) 0·04 (0·10) 0·05 (0·07)
>60 years NA –0·07 (0·13) –0·15 (0·19) NA
Provider is female –0·10 (0·11) –0·35† (0·01) –0·04 (0·07) –0·21† (0·07)
Cadre
Physician/medical officer‡ Ref Ref Ref Ref
Nurse/midwife –0·10 (0·11) –0·30† (0·08) –0·21* (0·08) –0·45† (0·09)
Community health worker –0·24† (0·08) –0·34†(0·08) NA NA
Other§ –0·35 (0·27) –0·41† (0·10) NA –0·15 (0·18)
Facility characteristics
Facility type
Dispensary Ref Ref Ref Ref
Health centre 0·01 (0·10) 0·08 (0·09) 0·28† (0·08) 0·29† (0·08)
District hospital –0·07 (0·13) 0·45† (0·11) 0·42† (0·12) 0·17 (0·21)
Location
Urban Ref Ref Ref Ref
Rural –0·18* (0·08) 0·04 (0·04) –0·08 (0·08) 0·02 (0·09)
Facility is public 0·10 (0·08) 0·03 (0·11) 0·00 (0·08) 0·02 (0·09)
Equipment index¶ 0·59 (0·35) 0·19* (0·07) –0·02 (0·25) 0·34* (0·15)
Data analysed were from Service Delivery Indicator surveys from Kenya (2012), Nigeria (2013), Tanzania (2014), and 
Uganda (2013). Data are coefficients from ordinary least squares regressions, with the log(clinical guidelines score) as the 
dependent variable and robust SEs in parentheses. The clinical guideline score was calculated as the share of all tasks 
expected to be done (eg, patient history, symptoms, physical exam) when a patient presents with diabetes symptoms. 
NA=not applicable. *p≤0·05. †p≤0·01. ‡Also includes clinical officers. §Includes paraprofessionals and lab technicians. 
¶Equipment index was calculated as the share of four essential equipment available and functioning at facilities: 
sphygmomanometer, thermometer, stethoscope, and weighing scale.
Table 8: Ordinary least squares regression results with the log of the clinical guideline score as the 
dependent variable
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Bommer and colleagues.204 Analysing direct health 
expenditure and indirect costs of diabetes, that study 
estimated the global economic burden in adults in 2015 
to be US$1·31 trillion, equivalent to 1·8% of global GDP.
Using prevalence and mortality data from the IDF 
Diabetes Atlas,25 the study204 estimated direct costs based 
on countries’ per-capita health expenditure, assuming 
literature-derived ratios between age-specific and sex-
specific treatment costs for people with and without 
diabetes. These ratios varied between HICs and LMICs, 
between women and men in HICs, between rural and 
urban areas in LMICs, and between people with 
diagnosed versus undiagnosed diabetes, thus extending 
previous work by the IDF.25 Note, however, that no 
appropriate studies for sub-Saharan Africa could be 
identified, and thus the applied cost ratios might not 
fully reflect the situation in the region. Indirect costs 
were defined as productivity losses due to mortality or 
disability, as measured by foregone labour earnings. As 
wage data from sub-Saharan African countries are scarce, 
labour earnings were proxied by the labour income share 
in GDP per working age person, as measured in 
2015 US$. A more detailed discussion of the method is 
provided elsewhere204 and in the appendix 1.
Based on the same approach as that used by Bommer 
and colleagues,204 and using national account data from 
the World Development Indicators database12 for 
47 countries in sub-Saharan Africa, we estimated the 
overall costs of diabetes in 2015 for sub-Saharan Africa to 
be US$19·45 billion, or 1·2% of cumulative GDP of the 
entire region. About $8·64 billion (44·4%) of this burden 
arose from indirect costs. About $12·10 billion (62·2%) 
arose from southern Africa, mainly from the relatively 
wealthy South Africa, and only $1·70 billion (8·7%) arose 
from western Africa. The share of indirect costs by region 
varied from 23·2% to 49·2% (figure 8).
Productivity losses consisted of four components: 
premature mortality, which amounted to $7·86 billion 
(91·0%) of total indirect costs; diabetes-related 
complications and malaise, leading to workforce dropout, 
which accounted for $0·53 billion (6·2%) of total indirect 
costs); sick leave (absenteeism), which accounted for 
$0·17 billion (1·9%) of total indirect costs; and decreased 
productivity while working (presenteeism), which 
amounted to $0·07 billion (0·9%) of total indirect costs 
(figure 9). These estimates provide important 
benchmarks for the economic value that could be 
generated through improvements in initiatives to address 
diabetes risk factors, prevention, and early diagnosis.
An important question for policy makers in sub-
Saharan Africa is how the economic costs of diabetes are 
going to evolve in the short and medium term. To predict 
economic costs of diabetes over time, we followed 
previous projection attempts by the IDF25 by using 
quinquennial UN Population Prospects data for the 
years 2015–30 (using the medium variant provided by the 
UN Population Division),216 as well as projected 
urbanisation rates from the UN.217 Both demographic 
changes and urbanisation rates are likely to be substantial 
drivers of future costs because an urban sedentary 
lifestyle is considered an important risk factor for 
diabetes.218 Our projected economic costs also take into 
consideration real GDP and GDP per-capita growth 
(extrapolated based on past growth rates obtained from 
the World Bank).12
100% 
50% 
37% 
17% 
11% 
Total people
with diabetes
Glucose measured Aware of diagnosis Advice received Medication 
received
–50 percentage 
points
–13 percentage 
points
–20 percentage 
points
–6 percentage 
points
Figure 7: Cascade of care for diabetes based on population survey data from 12 sub-Saharan African countries 
(2005–15)
This figure depicts the diabetes cascade of care based on data from 10 STEPS surveys (Benin, Comoros, Guinea, 
Kenya, Liberia, Mozambique, Seychelles, Tanzania, Togo, and Uganda), the Namibia Demographic and Health 
Survey, and the South Africa Nutrition and Health Examination Survey. All surveys were done during the period 
from 2005 to 2015. By use of individual-level data from these surveys, we created a diabetes care cascade, which 
shows the percentage of the total population with diabetes that self-reported reaching each subsequent step in 
the care process, conditional on having reached the previous step. See Panel 5 on how diabetes was defined. All 
numbers displayed represent the percentage of the total number of people with diabetes in the sample.
Panel 5: Constructing the diabetes care cascade
When constructing the diabetes care cascade, diabetes was defined based on the current 
WHO and American Diabetes Association diagnostic criteria as a fasting plasma glucose 
concentration of more than or equal to 7·0 mmol/L (126 mg/dL), a 2 h plasma glucose 
concentration of more than or equal to 11·1 mmol/L (200 mg/dL), or a HbA1c 
measurement of 6·5% (48 mmol/mol) or higher.136,137 This definition represents the gold-
standard clinical practice guidelines that are being used internationally. The data had one 
or more of these measures for each individual surveyed (appendix 1).
Those individuals reporting use of medication for diabetes were also classified as having 
diabetes, irrespective of the biomarker values. Respondents who self-reported a diagnosis 
of diabetes, but were not on medication and lacked the criteria indicated above, were not 
classified as diabetic. Additionally, we quantified met need for four different metrics of 
diabetes care in the population with diabetes: ever having received a blood glucose 
measurement as a measure of diagnosis (before the STEPS or other survey with which the 
diagnosis was made); for those who had received a blood glucose measurement, ever 
having been told about the diagnosis of diabetes as a measure of awareness of diagnosis; 
receipt of any advice from a health-care provider to lose weight or exercise; and use of 
either oral medications or insulin for treatment of diabetes.
Using these metrics, we constructed a diabetes care cascade for each of the 12 countries 
for which data were available. This cascade, created with individual-level data, shows the 
percentage of the total population with diabetes that self-reported reaching each 
subsequent step in the care process, conditional on having reached the previous step.
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We considered three scenarios for the evolution of age-
group-specific and sex-specific diabetes prevalence and 
mortality. First, we used the optimistic assumption that 
age-group-specific and sex-specific diabetes mortality 
and prevalence stay constant over time (scenario A). 
Second, we let the age-group-specific and sex-specific 
diabetes prevalence and mortality increase, depending 
on a country’s income-group classification according to 
the World Bank and adult diabetes prevalence in 2015, as 
shown in table 9 (scenario B). The rationale for this 
approach was the assumption that middle-income 
countries will increasingly adopt western sedentary 
lifestyles and consumption patterns. This trend is likely 
to be less pronounced in LICs where restricted 
household budgets constrain rapid changes in 
consumption patterns. Third, in scenario C, we doubled 
all growth rates from scenario B. Thus, our projections 
cover very optimistic to very pessimistic outlooks.
In addition to changes in prevalence and mortality, the 
growth of direct costs depends in part on remuneration of 
health personnel; Organisation for Economic Co-
operation and Development data suggested that 
compensation of health workers accounted for up to 57% 
of total health expenditure during the past decade, and we 
assumed sub-Saharan African health sectors to be 
particularly labour intensive.219 Similarly, the increase in 
indirect costs depends on the evolution of average annual 
wages. For all projection scenarios, we assumed that both 
average wages and the remuneration of health personnel 
grow at the same rate as real GDP per capita.
Our estimates suggest that the economic costs of 
diabetes  for sub-Saharan Africa will increase from 
US$19·45 billion (1·2% of GDP) in 2015 to $35·33 billion 
(1·1% of GDP) in 2030, according to scenario A; to $47·33 
billion (1·4% of GDP) in 2030, according to scenario B; 
and to $59·32 billion (1·8% of GDP) in 2030, according 
to scenario C (measured in 2015 prices; figure 10).
While all projection scenarios place southern Africa on 
top, with an increase from US$12·10 billion in 2015 to 
$17·15–$29·20 billion in 2030 depending on the scenario, 
we also predict substantial growth in absolute costs in 
eastern Africa (from $3·82 billion in 2015 to up to 
$16·21 billion in 2030 for scenario C; figure 10). Relative 
to GDP, southern Africa is again predicted to bear the 
largest economic burden in all projection scenarios 
(from 3·5% in 2015 to between 3·4% for scenario A and 
5·8% for scenario C in 2030; figure 10).
Despite uncertainties about the future evolution of 
diabetes prevalence and diabetes-related mortality, and 
future GDP growth, the numbers are alarming. The 
high direct and indirect economic burden sub-Saharan 
Africa is predicted to face creates a strong incentive for 
policy makers to increase efforts to prevent diabetes and 
reduce diabetes-related complications and premature 
mortality. However, as the analysis in this report shows, 
health systems in sub-Saharan African countries are ill-
prepared to effectively manage diabetes; the existing 
Panel 6: Labour-market effects of diabetes
Based on a systematic review and assessment of the available 
empirical evidence on the labour-market effects of diabetes, a 
global cost-of-illness study204 estimated that the reduction in 
labour-force participation of individuals with diabetes in 
high-income countries (HICs) was 12·6% for men and 
25·2% for women. Conversely, in low-income and 
middle-income countries (LMICs), reduction in labour-force 
participation ranged from 1·1% to 13·2% for men and 
from 1·2% to 17·4% for women. Moreover, in high-income 
settings, men and women with diabetes who were in the 
labour force were found to be absent from work for 1·9–4·3 
additional days per year, whereas the corresponding numbers 
in LMICs ranged from 1·9 to 8·6 excess days for men and 
from 2·8 to 10·2 excess days for women. Finally, productivity 
losses while at work (presenteeism) in people with diabetes 
were found to be 0·3% in HICs and 0·6–1·0% in LMICs.
The underlying empirical evidence largely draws on data from 
HICs and upper-middle-income countries. Effects on labour-
market dropout and presenteeism are based on studies from 
the USA207,208 and Mexico.209,210 Although the diversity of 
sources is larger for absenteeism—with studies from the 
USA,211 Mexico,210 India,212 Iran,213 and Namibia214—it is unclear 
to what extent these labour-market effects accurately capture 
the situation in sub-Saharan Africa. For instance, the 
combination of limited capabilities for management of blood 
sugar levels and a shortage of preventive treatment is likely 
to lead to high rates of severe complications in the long term, 
hence potentially increasing the rate of labour-force dropout.
19·45 (44·4%)
1·83 (42·2%)
3·82 (39·7%)
1·70 (23·2%)
12·10 (49·2%)
0 10 20 30 40
Economic costs in billion US$
All sub-Saharan
Africa
Middle Africa
Eastern Africa
Western Africa
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Direct costs
Indirect costs
Figure 8: Economic burden of diabetes in sub-Saharan Africa (2015)
Numbers in parentheses are percentages of indirect costs in total costs. Data are 
from the World Development Indicators database12 and are for 47 countries in 
sub-Saharan Africa. Estimates for southern Africa include Botswana, Lesotho, 
Namibia, South Africa, and Swaziland. Estimates for western Africa include 
Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, 
and Togo. Estimates for eastern Africa include Burundi, Comoros, Eritrea, 
Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, 
Seychelles, South Sudan, Sudan, Tanzania, Uganda, Zambia, and Zimbabwe. 
Estimates for middle Africa include Angola, Cameroon, Central African Republic, 
Chad, Democratic Republic of the Congo, Republic of the Congo, 
Equatorial Guinea, Gabon, and São Tomé and Príncipe.
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health-systems response is weak, the care provided is 
suboptimal, and the unmet need is very large. If diabetes 
is effectively managed, its future health and economic 
burden could be substantially reduced. The following 
sections therefore point to potential health policies that 
might help sub-Saharan African countries to better cope 
with the challenges imposed by diabetes, and discuss the 
potential benefits that could be realised if diabetes in 
sub-Saharan Africa was to be managed according to 
international guidelines and evidence.
Benefits of scaling up diabetes interventions in 
sub-Saharan Africa
For people with diabetes, the three principal coexisting 
risk factors leading to morbidity and mortality are high 
blood pressure, disordered lipid profile, and poor 
glycaemic control; an aim of good diabetes care is to 
prevent their long-term complications. Although all three 
risk factors have been associated with macrovascular and 
microvascular complications, substantial differences exist 
in their relative effects, in terms of the complexity of their 
treatment and monitoring regimens, their therapeutic 
window, and the costs of therapy. Important interactions 
exist between these risk factors for both macrovascular 
(coronary heart disease, stroke) and microvascular 
(retinal, renal, neuropathic) complications of diabetes,220,221 
with treatment guidelines emphasising the importance of 
addressing all three.222
For both blood pressure and lipid therapies, there has 
been a move towards targeting treatment to individuals 
at increased levels of risk, rather than according to levels 
of blood pressure or lipids, with the understanding that 
different individuals might experience different benefits 
and risks from therapy depending on their comorbid 
conditions. For example, people with previous 
myocardial infarction or stroke might benefit from 
initiation of treatment at lower levels of blood pressure 
or LDL-cholesterol than those who have not had a 
previous cardiovascular event. The risk-based approach 
to treating blood pressure, termed benefit-based tailored 
treatment (BTT), has been shown to be more effective 
and less costly than treating blood pressure to target 
levels (the so-called treat-to-target [TTT] strategy).223 
Additionally, when considering blood pressure, lipid, 
and glycaemic control in patients with diabetes, in 
countries with poor insulin availability (eg, many 
LMICs), BTT was shown to be more clinically effective 
and cost-effective than TTT for preventing microvascular 
and macrovascular complications. When insulin was 
available, the BTT strategy was no longer superior to the 
TTT strategy for preventing micro vascular disease.152
Using the same model as used in our previous study,152 
we tested, with a microsimulation model, whether a BTT 
approach compared with the status quo (ie, currently 
received care) or a TTT approach compared with the 
status quo would be beneficial to people with diabetes in 
countries in sub-Saharan Africa for overall management 
of diabetes risk factors. A summary of the methods is 
shown in panel 7. We found that, from a population 
perspective, a BTT strategy would be more effective and 
cost-effective than a TTT strategy (table 10). Although a 
similar proportion of people with diabetes would typically 
be recommended treatment of any kind (for example, a 
mean of 86·4% under the TTT strategy vs 88·4% under 
the BTT strategy in Malawi; table 10), those typically 
treated with the BTT strategy would be treated more 
intensively (for example, 4·5 vs 3·5 medications per 
person in Malawi; table 10).
Compared with the TTT strategy, the BTT strategy 
would recommend significantly more adults with 
diabetes to receive blood-pressure-lowering drugs and 
would non-significantly increase the number of patients 
treated with statins and glucose-lowering therapies 
(table 10). Additionally, the BTT strategy was estimated to 
avert two-to-four times as many macrovascular events 
(myo cardial infarction and stroke) as the TTT strategy 
over a period of 10 years, although the number of 
micro vascular events did not significantly differ between 
the two strategies.
Prevalence ≤3% Prevalence >3% 
to ≤7·5%
Prevalence >7·5%
Low-income countries 0%/35%/70% 0%/20%/40% 0%/5%/10%
Middle-income countries 0%/50%/100% 0%/35%/70% 0%/17·5%/35%
High-income countries 0%/25%/50% 0%/10%/20% 0%/2·5%/5%
Data are the assumed growth in age-group-specific and sex-specific prevalence and mortality from 2015 to 2030 for 
scenarios A/B/C, depending on 2015 adult prevalence and income classification. Data for 2015 come from the 
International Diabetes Federation Diabetes Atlas.25 Growth rates for high-income countries with low or medium 
diabetes prevalence are only provided for reference, since no country in sub-Saharan Africa fell into this category.
Table 9: Summary of scenarios for the evolution of age-group-specific and sex-specific prevalence and 
mortality by income group and 2015 adult prevalence for countries in sub-Saharan Africa
91·0% ($7·86 bn)
1·9% ($0·17 bn)
0·9% ($0·07 bn)
6·2% ($0·53 bn)
Mortality
Presenteeism
Absenteeism
Dropout
Figure 9: Distribution of indirect costs of diabetes in sub-Saharan Africa (2015)
Data are authors’ estimates. Productivity losses consisted of four components: 
premature mortality, reduced labour-force participation due to diabetes-related 
complications and malaise (dropout), increased likelihood of taking sick leave 
(absenteeism), and decreased productivity while working (presenteeism). 
Downloaded for Anonymous User (n/a) at Aga Khan Hospital from ClinicalKey.com by Elsevier on September 07, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
650 www.thelancet.com/diabetes-endocrinology   Vol 5   August 2017
The Lancet Diabetes & Endocrinology Commission
12·10
12·10
12·10
13·77
15·23
16·45
15·39
18·81
21·94
17·15
23·18
29·20
1·70
1·70
1·70
2·22
2·52
2·76
2·89
3·74
4·50
3·77
5·55
7·33
3·82
3·82
3·82
5·29
5·74
6·12
7·39
8·70
9·91
10·36
13·29
16·21
1·83
1·83
1·83
2·37
2·59
2·79
3·09
3·70
4·27
4·05
5·31
6·58
19·45
19·45
19·45
23·65
26·08
28·11
28·76
34·96
40·63
35·33
47·33
59·32
0 10 20 30 40 50 60 70 80 90
0 10 20 30 40 50 60 70 80 900 10 20 30 40 50 60 70 80 90
Southern Africa Western Africa Eastern Africa
Middle Africa All sub-Saharan Africa
Economic costs in billion US$ Economic costs in billion US$
Economic costs in billion US$
2015
2020
2025
2030
2015
2020
2025
2030
2015
2020
2025
2030
2015
2020
2025
2030
Scenario A
Scenario B
Scenario C
0 2 4 6 8
0 2 4 6 8 0 2 4 6 8
Economic costs in percentage of GDP
Economic costs in percentage of GDP Economic costs in percentage of GDP
All sub-Saharan Africa
Southern Africa Western Africa Eastern Africa
Middle Africa
A
B
5·8
4·6
3·4
4·9
4·2
3·5
4·2
3·9
3·5
3·5
3·5
3·5
0·5
0·4
0·4
0·3
0·3
0·3
0·3
0·3
0·3
0·3
0·3
0·3
1·5
1·2
1·2
1·1
1·1
0·9
0·9
0·9
0·9
0·9
1·0
1·0
1·7
1·4
1·4
1·4
1·4
1·1
1·1
1·1
1·5
1·3
1·3
1·1
1·2
1·2
1·2
1·2
1·2
1·1
1·0
1·0
1·0
1·0
1·8
1·6
Figure 10: Projected 
economic costs of diabetes 
in sub-Saharan Africa 
(2015–30) 
Data are authors’ estimates. 
(A) Absolute costs; dark 
shades indicate direct costs. 
(B) Costs as a percentage of 
GDP. Scenario A assumes 
constant age-group-specific 
and sex-specific prevalence, 
whereas scenarios B and C 
allow growth rates to vary 
with initial prevalence and 
country-income level. 
GDP=gross domestic product.
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With the TTT strategy, the estimated total drug costs in 
the countries studied would be US$1346·6 million 
(95% CI $471·1–2206·7 million; 2016 prices) over the 
simulated period of 10 years, whereas with the BTT 
strategy, the estimated total drug costs would be higher at 
$1407·9 million ($464·7–$2332·5 million). In terms of 
total DALYs averted, the benefits of BTT were estimated 
to be superior (table 10), with BTT saving 1·89 million 
DALYs (0·89–3·38 million) and TTT saving 1·16 million 
DALYs (0·55–2·07 million) in the simulated period of 
10 years in sub-Saharan African countries. With BTT, 
the mean costs per DALY averted were $743·4 
($137·5–$2627·2) for the BTT strategy and $1159·5 
($227·6–$4047·5) for the TTT strategy (table 10).
These results show that there are potentially substantial 
benefits for scaling up diabetes services to address unmet 
need. The question remains as to whether countries will 
be able to strengthen health systems to respond to those 
needs.
Service delivery models for managing diabetes 
in sub-Saharan Africa
Encouraging examples of successful models of diabetes 
care are emerging in LICs and in sub-Saharan Africa. In 
this section, we explore these models and provide country-
case examples of innovative approaches introduced in 
sub-Saharan Africa to effectively manage diabetes to 
show what might be possible in the future.
Panel 7: Benefits of managing diabetes using a benefit-based tailored treatment or treat-to-target strategy in 
sub-Saharan Africa
We constructed a microsimulation model, which simulates 
individuals with diabetes by sampling from correlated 
probability distributions describing the relationships between 
demographics and risk factor values in the populations of 
interest. Individual demographics included age and sex, with 
population sizes taken from the UN Population Division’s 
projections for 2015–25, and the subset of the population 
expected to be born or already alive with diabetes during this 
period based on International Diabetes Federation estimates 
for diabetes prevalence and trends for the age group of 30–70 
years.12 The microsimulation model (method published in 
detail elsewhere152 and described in the appendix 1) enabled 
us to compare the approaches to reducing the risk of major 
macrovascular (myocardial infarction, stroke) and 
microvascular (neuropathy, retinopathy, and end-stage renal 
disease) complications of diabetes in two populations aged 
30–70 years in sub-Saharan Africa: one from 
Malawi (n=35 730), who are participants in the Karonga 
Prevention Study,224 and the other from combined datasets 
from Ghana and South Africa (n=3938 and 2352, 
respectively), representing sub-Saharan Africa (see appendix 1 
for methods).
The methods and limitations have been described in detail 
elsewhere.152,223 Briefly, two alternative management 
approaches were compared. The first was a treat-to-target 
(TTT) strategy involving titration of blood pressure medication, 
statins, and glucose-lowering drugs to predefined targets. Thus, 
the TTT strategy involved treating individuals with blood 
pressure medication until they achieved a blood pressure of less 
than 130/80 mm Hg;225 with a statin until they achieved an LDL 
concentration of less than 2·59 mmol/L (100 mg/dL);226 and 
with metformin and sulfonylureas (and, if needed, substituting 
the sulfonylurea with insulin) until they achieved an HbA1c level 
of less than 7%.136,137
The second strategy was a benefit-based tailored treatment 
(BTT) strategy, which involved treating individuals at high 
risk of macrovascular complications with blood pressure 
medication and statins, and those at high risk of 
microvascular complications with glucose-lowering agents, 
until they achieved low risk levels. Specifically, the BTT 
strategy involved treating individuals with a 
10-year combined risk (assessed using UKPDS outcomes 
model 2—see appendix 1 for further details) of myocardial 
infarction and stroke of more than 10% with antihypertensive 
drugs and a statin until their risk was lowered to below the 
10% threshold (provided blood pressure remained 
>110/55 mm Hg for safety). Additionally, the strategy 
involved treating those with a lifetime risk of the three major 
microvascular complications (blindness, end-stage renal 
disease, and amputation secondary to neuropathic ulcer) of 
more than 4% with metformin and sulfonylureas (and, if 
needed, substituting the sulfonylurea with insulin) until 
lifetime microvascular risk was below 4% (provided fasting 
blood glucose remained >3·33 mmol/L [60 mg/dL] for 
safety).
We compared each method with the current situation in each 
individual country and then compared the average 
cost-effectiveness ratios of the BTT and TTT strategies. We used 
WHO guidelines227 to choose blood pressure and statin 
medications and the Yale Diabetes Center Guidelines228 for 
dose-escalation algorithms for metformin, sulfonylureas, and 
insulin.
Cases averted, disability-adjusted life-years (DALYs) saved 
(based on disability weight values estimated by the Global 
Burden of Disease study229), and drug costs for therapy (based 
on per-unit global buyer cost estimates from the International 
Medical Products Price Guide192) were integrated over the 
simulated lifecourse of all people with diabetes who were alive 
or born during the next 10 years using the projected estimates 
for the population and those with diabetes, as per standard 
cost-effectiveness guidelines.230 Additional service delivery costs 
were assumed to be the same for each strategy. DALYs and 
costs were discounted at a 3% annual rate, the rate used by 
WHO,231 and costs are expressed in 2016 US dollars.
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We reviewed published studies of existing approaches 
to diabetes care in sub-Saharan Africa (see appendix 1 
for methods). We also did case studies to examine 
current practices in seven countries (Botswana, 
Ethiopia, Kenya, Malawi, Mali, Rwanda, and South 
Africa; see appendices 2–8 for details), using a 
framework that has been used previously to analyse 
different disease programmes233–237 in several settings238 
and that was adapted for diabetes. Additionally, we 
examined how existing and new technologies could be 
harnessed to help improve management of diabetes in 
sub-Saharan Africa.
Our literature review identified 467 studies, of which 
32 from 11 different countries (Cameroon, Eritrea, 
Ethiopia, Ghana, Kenya, Malawi, Mozambique, South 
Africa, Sudan, Tanzania, and Uganda) met the inclusion 
criteria (ie, if they described or evaluated a new or 
previously existing model of diabetes care in sub-
Saharan Africa; appendix 1). The review showed that, in 
many sub-Saharan African countries, diabetes care is 
still mostly available only in the hospital setting, 
requiring patients to travel great distances to access 
services and follow-up care important for effective 
diabetes management. However, several countries have 
seen success with the introduction of new, decentralised 
care-delivery models for management of diabetes (eg, 
in primary health centre, community, or home settings), 
with an emphasis on use of nurses and community 
health workers, patient education, and community 
engagement.
Cameroon and Tanzania have introduced community-
based management of diabetes.239 In Cameroon, facility-
based interventions for high blood pressure and diabetes, 
involving task shifting and nurse-led care in rural health 
districts, significantly improved patient retention in 
cardiovascular disease management programmes.240 
Malawi (n=8 632 000 people aged 30–70 years, 
about 604 000 with diabetes)
Sub-Saharan Africa (n=318 850 000 people aged 
30–70 years, about 24 870 000 with diabetes)
TTT BTT TTT BTT
Adults with diabetes recommended 
treatment, thousands
522·0 
(86·4% [85·4–87·4%])
534·1 
(88·4% [87·4–90·0%])
23 942·7 
(96·3% [95·2–97·3%])
21 688·3 
(87·2% [65·6–100·0%])
Blood pressure treatment 300·9 
(49·8% [40·0–59·6%])
490·6 
(81·2% [72·4–90·0%])
13 800·9 
(55·5% [44·6–66·4%])
19 922·6 
(80·1% [54·3–100·0%])
Lipid treatment 478·6 
(79·2% [62·6–95·8%])
490·6 
(81·2% [72·4–90·0%])
20 420·1 
(82·1%[67·4–100%])
19 922·6 
(80·1% [54·3–100·0%])
Glycaemic treatment 300·3 
(49·7% [47·9–51·5%])
313·8 
(51·9% [50·0–53·8%])
12 814·1 
(51·5% [51·5–52·7%])
13 387·9 
(53·8% [53·8–55·0%])
Number of medications per person for 
recommended treatment
3·5 (3·2–3·8) 4·5 (4·3–4·7) 3·6 (3·5–3·9) 4·3 (4·2–4·5)
Percentage of those on glycaemic 
treatment requiring insulin
19·4% (17·4–21·4%) 20·3% (18·2–22·4%) 20·1% (18·7–21·9%) 21% (19·6–22·9%)
Macrovascular events prevented per 10 years, thousands
Myocardial infarction 2·4 (2·2–2·7) 9·6 (7·6–11·4) 108·9 (103·8–122·4) 226·2 (182·5–268·3)
Stroke 3·8 (3·5–4·2) 13·7 (11·5–15·8) 174·4 (163·0–189·1) 322·8 (276·0–371·3)
Microvascular events prevented per 10 years, thousands
Blindness 0·6 (0·2–2·4) 0·6 (0·1–2·3) 26·6 (8·7–105·4) 25·9 (5·5–95·9)
End-stage renal disease 0·6 (0·1–0·5) 0·6 (0·0–0·3) 26·6 (3·6–23·9) 25·9 (0·5–11·4)
Amputation 1·5 (0·2–2·7) 1·6 (0·3–4·2) 66·4 (10·7–118·8) 69·4 (11·5–182·8)
Deaths averted per 10 years, thousands 4·7 (0·5–10·2) 14·0 (1·6–31·7) 212·6 (25·7–454·2) 358·0 (40·4–833·7)
Number needed to treat to prevent 
one macrovascular event per 10 years
83·9 (75·3–92·4) 23·0 (19·6–27·9) 84·5 (76·9–89·7) 39·5 (33·9–47·3)
Number needed to treat to prevent 
one microvascular event per 10 years
193·2 (91·8–1042·9) 189·2 (78·6–1355·5) 200·3 (96·5–1041·9) 178·9 (74·8–1238·0)
Cost and cost-effectiveness
Total drug costs per 10 years, 
thousand US$ (2016 values)
31 443·3 
(10 612·4–51 794·0)
33 577·7 
(12 020·7–53 600·4)
1 346 617·9 
(471 138·5–2 206 655·0)
1 407 869·7 
(464 664·0–2 332 519·3)
Total DALYs averted per 10 years, 
thousands
25·8 (11·6–46·7) 73·2 (36·5–124·6) 1161·3 (545·2–2070·2) 1893·9 (887·8–3380·4)
$ per DALYs averted 1221 (227·3–4476·8) 459 (96·5–1466·9) 1159·5 (227·6–4047·5) 743·4 (137·5–2627·2)
Data are n (% [95% CI]) or n (95% CI). 95% CIs were estimated from 10 000 repeated simulations of the model in which the probability distributions of all input parameter 
values were repeatedly sampled to identify uncertainty in the outcome metrics shown. Data to represent sub-Saharan African countries were drawn from cohorts from Ghana 
and South Africa obtained from the WHO Study on Global Ageing and Adult Health.232 For more detail on methods, see panel 7 and appendix 1. BTT=benefit-tailored therapy. 
TTT=treat-to-target strategy. DALY=disability-adjusted life-year. 
Table 10: BTT versus TTT in a microsimulation model of treatment for people with diabetes in Malawi, and in sub-Saharan Africa generally
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Similarly, in Kenya, management of high blood pressure 
and diabetes has been delegated to rural primary health-
care clinics, with good retention rates and control.241 In 
Ethiopia, physicians and diabetes-trained nurses travel 
from hospitals to rural medical centres for training and 
care provision, with early encouraging results in 
improving access to services.242,243
In the public sector in South Africa, a chronic disease 
outreach programme, which used nurses in primary 
health centres to provide educational and follow-up 
advice to patients with diabetes, improved early detection 
and referral of high-risk, poorly controlled patients to 
specialist centres.244 Decentralisation of diabetes 
management to the community level was also successful 
in the private sector in South Africa, where the care of 
diabetes was transferred to physicians working in 
community-based primary health centres affiliated with 
a diabetes and endocrinology centre. The scheme used 
community-based capitation and a financial  risk-sharing 
model for diabetes and led to major reductions in 
hospital admissions for both acute metabolic 
emergencies and all causes, as well as reduced costs, 
delayed progression of microvascular complications, and 
improved outcomes.245
Nurse-led diabetes care, with a nurse-led protocol and 
education-based system, was also shown to be successful 
in rural KwaZulu-Natal in South Africa, with improved 
control of HbA1c and increased satisfaction for patients, 
their families, and health workers.246,247 Although the 
improvements in glycaemic control achieved at 18 months 
following the introduction of that scheme were not 
sustained at 48 months, mean HbA1c concentrations at 
48 months were lower than at baseline.247 Similar to South 
Africa, the introduction of protocol-driven, nurse-led 
management of diabetes in primary health-care centres in 
rural and urban Cameroon also led to improvements in 
glycaemic control and blood pressure.248 However, a 
study249 of a community-health-worker model of outpatient 
care introduced in South Africa for diabetes and 
hypertension—which involved monthly home visits, 
counselling services, and access to monthly supplies of 
medication—showed improved control of hypertension 
but not of diabetes, with 11 (26%) of 42 patients at the 
clinic showing improved glycaemic control compared 
with only two (9%) of 22 patients visited at home by 
community health workers.
Combined with decentralisation of services, plans to 
specifically integrate care have been successful. In 
Cameroon, integration of care for high blood pressure 
and diabetes was effectively achieved in eight rural health 
districts by task shifting to health-care facilities with non-
physician clinicians, with improved control of risk factors 
in patients attending those services.249
In South Africa, home glucose monitoring with urine 
testing was introduced 30 years ago, including for 
illiterate patients with diabetes, with good compliance 
and lower random glucose levels in compliers than in 
non-compliers.250 In Kenya, a home glucose monitoring 
programme that used mobile phones to enable 
community health workers to regularly communicate 
with patients to modify the dose of insulin injections 
helped to improve HbA1c concentrations.251,252
Patient education has also been used in several settings 
to improve services across the care continuum and to 
decentralise care away from hospitals to the patient level. 
For example, in Cameroon, motivational counselling and 
education were integrated into a screening programme to 
improve rates of follow-up for patients newly diagnosed 
with diabetes.253 In South Africa, group education was 
used at community health centres to improve patients’ 
knowledge and management of diabetes, although no 
improvements were seen in diabetes self-care activities, 
weight loss, HbA1c concentrations, quality of life, self-
efficacy, locus of control, blood pressure, waist 
circumference, or total cholesterol levels.144 Another 
study254 from South Africa showed that a group education 
programme for patients with type 2 diabetes could be 
implemented in rural areas with a dietitian or health 
promoter to provide a supportive environment for 
patients to learn and cope. That programme led to 
significant improvements in adherence to a diabetes-
appropriate diet, physical activity, foot care, and the 
perceived ability to educate others, although no significant 
change was seen in smoking or adherence to medication.254 
In Tanzania, a hospital-based education programme for 
children with type 1 diabetes about symptom 
management, correct insulin storage, and insulin 
administration led to reductions in severe hypoglycaemia, 
but no improvement in HbA1c concentrations.255 In 
Mozambique, twinning programmes have been used to 
successfully establish patient education programmes and 
to improve their effectiveness.185
In addition to patient education, health-provider 
education at hospitals and primary health-care centres, 
and at the community level, has been used to improve 
early recognition of diabetes and diabetic sequelae and to 
enhance disease management in sub-Saharan Africa. In 
Tanzania, where 70% of leg amputations occur in patients 
with diabetes,109 training of health-care personnel at 
different levels in diabetic foot management has led to 
improved case finding, earlier referrals, establishment of 
well functioning foot clinics, and strengthened 
management of diabetic foot ulcers, with better health 
outcomes.109 In Eritrea, a cooperative diabetes project that 
emphasised multidisciplinary training of physicians, 
laboratory scientists, diabetes nurse practitioners, patient 
educators, and dietitians, and improved quality of 
laboratory services, led to improved management of 
diabetes, with better HbA1c concentrations.256 Multi-
disciplinary training for diabetes, involving physicians, 
dietitians, nurse educators, and pharmacists, has also 
been introduced in Ghana to strengthen diabetes 
services,257 while training of patient educators has been 
introduced in Sudan.258
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In sub-Saharan Africa, electronic medical records,259 
treatment protocols, and guidelines260 have facilitated the 
development of primary care, community, and home-
based service models. For example, Malawi has 
successfully used existing service-delivery platforms and 
expertise in tuberculosis management, which has well 
established treatment guidelines and monitoring and 
reporting mechanisms, to introduce chronic disease 
management and reporting for diabetes.261
Integrating care of diabetes and hypertension into 
existing chronic care models for HIV has also been 
deemed a promising strategy. South Africa has used—in 
urban and peri-urban townships of the metropolitan 
region of Cape Town in Western Cape—mobile units for 
HIV counselling and testing as an entry point for 
combined screening of high blood pressure and diabetes, 
with a high yield of new cases, although linkage to care 
and follow-up was challenging.225 Community-based 
HIV-testing campaigns were used in Uganda to 
simultaneously offer diagnostic, preventive, treatment, 
and referral services for HIV, malaria, tuberculosis, high 
blood pressure, and diabetes, with effective linkage to 
care.262 In a study done in Kenya,252 HIV counsellors were 
trained to screen for diabetes and high blood pressure in 
home-based screening, and district hospital-based staff 
to do community-based screening; both approaches 
showed effective uptake, although, in both, follow-up 
levels were low, with only one-fifth of all patients screened 
returning after a random glucose test.
Diabetes management in Africa is strongly reliant on 
the non-physician health workforce, including nurses, 
community health workers, and health extension 
workers, as well as traditional healers in some settings. 
Several countries, such as Botswana, Ghana, Ethiopia, 
Kenya, Malawi, Mali, Rwanda, Tanzania, and South 
Africa, have introduced innovative approaches to address 
resource constraints when managing diabetes (see 
panel 8 for a summary of initiatives for and barriers to 
providing diabetes care in selected countries in sub-
Saharan Africa). In-country case studies for Botswana, 
Ethiopia, Kenya, Malawi, Mali, Rwanda, and South Africa 
are published as appendices 2–8.
Harnessing new technologies to improve 
diabetes care in sub-Saharan Africa
Improving access to existing technologies for better 
diabetes care in sub-Saharan Africa
New technologies for diabetes care have been developed 
for use in resource-rich health systems, but not for those 
in sub-Saharan Africa. In the region, the necessary 
technologies either do not exist (requiring the 
development of low-cost health technologies), or 
technologies exist but are not accessible because of high 
costs, or accessible technologies are not adopted because 
of health system barriers.
Most health technologies used to diagnose, monitor, 
and treat diabetes and its complications are not 
affordable for patients in sub-Saharan Africa. Patients 
experience difficulties in accessing health centres and, 
when they do, incur impoverishing expenditures.176,177,263–266 
Increased availability of low-cost and accurate 
diagnostics for point-of-care testing of blood glucose, 
HbA1c, glycosuria, and proteinuria could improve 
screening, diagnosis, treatment, and monitoring of 
diabetes and help to mitigate access constraints in 
delivering effective diabetes care, particularly when 
combined with a distributive model of primary-health-
centre-based and community-based services provided 
by community health workers (panel 8).
Ensuring timely and affordable access to existing cost-
effective technologies, such as appropriate forms of 
insulin,267 medicines, miniaturised blood glucose 
sensors, and strips for testing of urinary glucose or 
protein, is a challenge in sub-Saharan Africa. Improved 
technology assessment, procurement, and supply-chain 
management can help to achieve greater value for money 
and timely delivery of available medicines to avoid 
treatment interruptions and expand access.268
Strategies for improved use of cost-effective technology 
should emphasise both health technologies (eg, new 
therapeutics, diagnostics, and medical devices) and 
technologies for health (eg, communication and transport, 
which affect health). These strategies should foster 
investments in hard (infrastructure and equipment) and 
soft (information and communication technology [ICT], 
with data analytics as an example) technologies.
In sub-Saharan Africa, ICT has been used variously in 
HIV and tuberculosis programmes,269 but, overall, its use 
in health systems is low. Diabetes registries, which form 
the mainstay of diabetes care platforms in HICs, are only 
available in six (17%) of 35 countries that responded to 
the WHO survey in the entire WHO African region.83 
One possibility is to extend existing databases for HIV 
and tuberculosis to include diabetes and NCDs. In 
countries where no such systems exist, development of 
future-proof diabetes registries should be prioritised. 
The absence of legacy systems provides an opportunity to 
introduce cost-effective ICT solutions that use mobile 
telephones to facilitate data sharing.270–272 For example, 
existing solutions using cloud technologies offer an 
important opportunity to capture and integrate real-time 
data across multiple mobile phones, point-of-care 
devices, laboratory diagnostics, and electronic health 
records (panel 9).
Improving adoption and dissemination of new health 
technologies for diabetes care in sub-Saharan Africa
Factors that hinder adoption and dissemination of new 
technologies in sub-Saharan Africa include imprecise 
definition of the problem being addressed; complexity 
and scalability of the technology or intervention; 
resistance from the adoption system (eg, health 
professionals and service users); characteristics of the 
health system that create rigidities or provide inadequate 
See Online for appendices 2–8
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incentives; and poor recognition of the challenge of 
diabetes in the broader context (among the population 
and politicians), such that it is not considered an urgent 
and major societal challenge.281,282
As we have discussed, emerging care-delivery models 
for diabetes in sub-Saharan Africa have distinctive 
features: a public health approach, with simplification 
and decentralisation of care to primary health centres 
and communities and with strong reliance on a non-
physician health workforce (including nurses, 
community health workers, and health extension 
workers); community involvement; peer support; and 
self-management. Expanded access to existing tech-
nologies can help sub-Saharan Africa not to replicate 
western models of care, which often favour an expert-led 
approach, but to foster innovative delivery models that 
reflect the African context and to build on experience of 
the innovations in care delivery with HIV/AIDS.283,284
Creating a successful response to diabetes in 
sub-Saharan Africa  
Aligning with global targets
Health systems in sub-Saharan Africa are unprepared for 
the rapidly increasing burden of diabetes. Consequently, 
many people go undiagnosed, and those who are 
diagnosed are not screened for comorbidities, do not 
receive treatment, or are not adequately controlled. The 
resultant morbidity and mortality lead to immense 
human, economic, and societal losses.
The increasing prevalence of diabetes in sub-Saharan 
Africa reflects not just greater numbers of people with 
the disease, but also a changing phenotype. The approach 
to managing such a complex and heterogeneous disorder 
has to be multisectoral, with education, engagement, and 
cooperation of individuals, and with awareness and 
education of the community. Specific therapeutic 
measures are not enough; successful management of 
Panel 8: Health services for diabetes in sub-Saharan Africa: a summary of the Commission’s case reports of seven countries 
(see appendices 2–8 for more detail and references)
In Botswana, patients with diabetes have access to general 
nursing, psychological, and social work services, both in the 
private and public sectors. Community health workers and 
diabetes youth leaders provide education and public health 
screening campaigns.
In Ethiopia, diabetes services are delivered mainly at primary 
health centres. Specialist clinics located in the major university 
teaching hospitals also provide diabetes care by endocrinologists 
or general internists. Nurses, health officers, and general 
practitioners provide most of the diabetes care in health centres 
and general hospitals. In 2014, an estimated six of ten health 
facilities, excluding health posts, provided diabetes care, 
although most patients with diabetes are undiagnosed.
After the launch of a national diabetes strategy in 2010, Kenya 
began to expand diabetes services, with training of health-care 
professionals and community health workers, development of 
national guidelines, and provision of diabetes screening. 
However, services at the level of the community and primary 
health centre are hampered by the inconsistent availability of 
drugs and diagnostic equipment.
Malawi has low numbers of health personnel and resource 
shortages, and patients with diabetes are underdiagnosed and 
poorly controlled. However, Malawi is piloting the WHO Package 
of Essential Noncommunicable Disease Interventions for 
Primary Health Care in Low-Resource Settings and set a target 
to give 1000 health workers specialist training by 2016. Malawi 
has introduced new service-delivery models for diabetes that 
mimic the directly observed treatment (short-course) approach 
used in tuberculosis care and home-based care and peer support 
used in management of HIV.
Rwanda is introducing clinical non-communicable disease 
(NCD) services and care packages across all health facilities 
and an NCD clinic model in district hospitals and health 
centres. The number of people living with diabetes and 
requiring close follow-up has increased. To address the 
shortage of health professionals and increasing demand for 
health care, Rwanda has introduced pre-service and in-service 
training for existing staff in the management of NCDs, started 
a programme of task shifting to transition chronic disease 
management to the home setting, and created a new cadre of 
health professionals (home-based care practitioners) at the 
community level to provide home-based services for diabetes 
and other NCDs.
In 2011, Tanzania established a National Diabetes Program as a 
collaboration between the Ministry of Health and Social Welfare 
and the Tanzania Diabetes Association—the implementing 
agency for the programme—that has used existing government 
facilities and staff to establish 148 diabetes clinics in zonal, 
regional, and district hospitals. Using funding from 
international agencies and the private sector, Tanzania’s 
National Diabetes Program provides funding for equipment 
and training of personnel to provide care for around 
800 000 people with diabetes. Diabetes care is provided free of 
charge to patients, and the government mandates that 
diabetes drugs should be given free of charge to patients using 
district and regional diabetes clinics.
In South Africa, diabetes care is provided in the public and private 
sectors, but huge inequities exist: the public sector provides for 
84% of the population and spends US$140 per person each year 
(4·2% of gross domestic product  [GDP]), whereas the private 
sector provides for 16% of the population and spends $1400 per 
person each year (4·3% of GDP). A network of national health 
laboratories provides services to more than 80% of the 
population for all standard diabetes-related investigations, but 
not all primary health clinics have access to standard diagnostic 
equipment because of budgetary constraints.
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For more on SUDOSCAN see 
http://www.sudoscan.com
For moreon NC-stat DPNCheck 
see http://www.dpncheck.com
diabetes in sub-Saharan Africa requires an enabling 
medical, social, and political context within which 
effective prevention, screening, diagnosis, treatment, 
and lifelong care can be delivered. In this respect, lessons 
can be learned from the HIV response in Africa, which 
successfully brought together governments, civil society, 
health-care providers, communities, donors, and the 
private sector.
The burden of diabetes in sub-Saharan Africa and its 
impact on individuals, populations, health systems, 
and economies means that policy makers must act to 
bring together wide-ranging stakeholders to spur action 
at country and global levels around a set of ambitious 
yet achievable targets, linked to those set in SDG 3: 
“ensure healthy lives and promote well-being for all at 
all ages”. Of the 13 targets set for SDG 3, six are most 
readily applicable to diabetes in sub-Saharan Africa: 
(1) by 2030, reduce by one-third premature mortality 
from NCDs through prevention and treatment; 
(2) achieve universal health coverage, including 
financial risk protection, access to quality essential 
health-care services and access to safe, effective, quality, 
and affordable essential medicines and vaccines for all; 
(3) strengthen the implementation of the WHO 
Framework Convention on Tobacco Control in all 
countries, as appropriate; (4) support the research and 
development of vaccines and medicines for the 
communicable diseases and NCDs that primarily affect 
Panel 9: Possibilities for affordable, cost-effective technologies for diabetes care in sub-Saharan Africa
Technologies to support diabetes diagnosis and 
management
Low-cost diagnostic devices that enable point-of-care testing 
of blood glucose, HbA1c, glycosuria, and proteinuria could be 
used for screening, diagnosis, treatment initiation, and 
monitoring. Yet, although low-cost, affordable devices do 
exist, such devices are produced by numerous manufacturers 
and often little compatibility exists between the necessary 
elements of the equipment (eg, blood glucose sticks) needed 
to use such devices, even for some manufacturers’ own 
models. Encouraging diagnostic device manufacturers to make 
changes towards greater interoperability will necessitate a 
more centralised approach to procurement of diagnostic 
devices used in the management of non-communicable 
diseases (NCDs). Moreover, international bodies such as WHO 
have an important part to play in developing the technical 
standards required for improved integrated diagnostic 
infrastructures for NCDs such as diabetes, just as these bodies 
did in strengthening diagnostic service infrastructures for 
infectious diseases such as HIV and tuberculosis. Improved 
interoperability of developed technologies that have 
interchangeable disposable components is needed to ensure 
that low-cost models can be used in low-income and middle-
income countries.
Results from such devices could be used in combination with 
mobile phones or smartphones to target messaging for 
preventive interventions,273 to communicate test results to 
patients,274 or to self-monitor diabetes (to help to improve 
adherence).275 Affordable diagnostic and communication 
technologies could help to transform diabetes care, as they 
have done for HIV management in resource-poor settings.276,277
Technologies to support screening for diabetes 
complications
Effective early detection of diabetic retinopathy, which might 
reduce the risk of blindness by 95%, currently requires both 
clinical staff with ophthalmological training and costly 
equipment to carry out eye examinations. Both requirements 
are a major obstacle to care, as shown by the case of Malawi, 
which has 17·8 million inhabitants but just nine 
ophthalmologists.278 New devices, such as the Portable Eye 
Examination Kit, which uses a smartphone, and the hand-held 
epiCam device, which captures images digitally for 
store-and-forward using a laptop computer, offer the possibility 
of screening for diabetic retinopathy by health workers in 
primary health centres, community-based services, and remote 
rural areas. Although these devices rely on expert analysis for 
interpretation of fundus images, diagnostic algorithms could be 
used to remotely analyse and grade images at low cost. For 
example, automated grading of fundus photographs is done 
within established services, including the Scottish National 
Diabetic Retinopathy Screening Programme, and has been 
studied in Nakuru, Kenya.279 However, reliable supporting 
infrastructure needs to be in place to allow the widescale 
adoption of such technology.
Peripheral neuropathy is another important complication of 
diabetes that has an urgent need for new diagnostic tools for 
early detection; the prognosis of diabetic peripheral neuropathy 
is poor if not diagnosed early. However, accurate diagnosis of 
diabetic peripheral neuropathy represents a major challenge, 
even in the context of resource-rich health systems.280 The 
development and adoption of new non-invasive diagnostic 
devices that enable point-of-care testing and do not require 
specialised training to use—eg, SUDOSCAN and 
NC-stat DPNCheck—could improve screening and early detection 
of diabetic peripheral neuropathy in resource-poor settings.
Technologies to support diabetes surveillance 
Cloud-based systems offer the possibility of capturing data 
from multiple sources and devices in real-time and integrating 
them. Data cloud solutions are low cost and more scalable than 
traditional data storage systems (which are reliant on hardware 
requiring constant electricity supply and regular servicing). 
By integrating data from multiple devices and sources, cloud 
solutions can help to manage the complex data needed for 
management of diabetes across multiple facilities and over long 
periods of time, and help to improve understanding of the 
epidemiology of diabetes and responses to interventions.
For more on the Portable Eye 
Examination Kit see 
http://www.peekvision.org
For more on epiCam see 
http://www.epipole.com/epicam
For more on SDG 3 see 
http://www.un.org/
sustainabledevelopment/health
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developing countries, and provide access to affordable 
essential medicines and vaccines; (5) substantially 
increase health financing and the recruitment, 
development, training, and retention of the health 
workforce in LICs, especially in the least developed 
countries; and (6) strengthen the capacity of all 
countries, in particular developing countries, for early 
warning, risk reduction, and management of national 
and global health risks (not just for infectious diseases, 
but also for diabetes and other NCDs).
Additionally, countries in sub-Saharan Africa should 
embrace the nine voluntary targets adopted at the 
65th World Health Assembly by member states as part 
of the WHO Global Action Plan for the Prevention and 
Control of NCDs 2013–20: to reduce premature 
mortality due to NCDs by 25%, to reduce physical 
inactivity by 10%, to reduce tobacco consumption 
by 30%, to achieve a 25% reduction in high blood 
pressure, to achieve 80% coverage of essential 
medicines and technologies for NCDs, and to achieve 
0% increase in the prevalence of obesity and diabetes 
by the year 2025.187 A Global Monitoring Framework 
underpins the Global Action Plan, with 25 indicators 
that are monitored by member states, of which 12 are 
relevant to diabetes and can be used to monitor 
achievements in sub-Saharan Africa.285
Achieving the targets set in SDG 3 and the Global 
Action Plan would undoubtedly help to transform the 
fight against diabetes in sub-Saharan Africa; avert 
needless suffering and death; and reduce the economic 
burden of diabetes on individuals, households, and 
societies. The crucial components of an effective 
response are solidarity and collective action at local, 
national, African, and global levels, with clear 
responsibilities for stakeholders as part of a collective 
response. The chief elements of this response, on which 
the Commissioners are in full agreement, are laid out 
below. We have also described operational targets that are 
achievable by 2020, 2025, and 2030 in panel 1.
Role of governments
Ultimately, governments should respond to the needs of 
their populations. In addition to enabling access to health 
services, governments should consider introducing 
public health measures to reduce NCDs, including 
banning smoking in public places, restricting advertising 
of unhealthy foods and beverages, creating or increasing 
taxes on cigarettes and sugar-sweetened beverages, and 
limiting portion sizes of sugar-sweetened beverages.43,286
A health-literate population is crucial for generating 
demand for health interventions, improving access to 
health systems, and ensuring uptake of preventive 
measures. Much health literacy in sub-Saharan Africa has 
come from successful media campaigns via radio and 
poster adverts and education through interaction with 
community health workers. These campaigns have 
generally focused on prevention of HIV (eg, condom use) 
and malaria (eg, use of insecticide-treated bednets),287 and 
have led to increased use of preventive interventions. 
Investment and research is now needed to build on these 
initiatives and to increase population awareness of 
diabetes and generate health-care demand for diabetes 
and NCDs. Therefore, we recommend that countries in 
sub-Saharan Africa research and develop locally 
appropriate media campaigns to educate the public about 
the symptoms of type 1 and type 2 diabetes and encourage 
those with symptoms to seek care. In particular, media 
campaigns should be deployed to educate citizens about 
preventive lifestyle measures, combined with government 
regulations that restrict advertisements for unhealthy 
foods.
We also recommend that governments should allocate 
sustainable funding to tackle the diabetes epidemic. As 
noted earlier, we have estimated that, in 2015, the 
economic burden of diabetes in sub-Saharan Africa was 
US$19·45 billion, or 1·2% of cumulative GDP of the 
whole sub-Saharan African region. Unchecked, this 
economic burden is projected to increase to between 
$35·33 billion and $59·32 billion by 2030 (figure 10).
Given the strong causal link between NCDs (including 
type 2 diabetes), sugar-sweetened beverages, salt, and 
tobacco, we strongly advise countries to consider raising 
revenues by taxing these products to fund health systems. 
Although all too often considered a disease of the rich, 
the burden of type 2 diabetes in sub-Saharan Africa is 
increasingly borne by the poor.21 Making available and 
encouraging healthy choices, and taxing unhealthy 
choices, should help to promote the health of the poorer 
sectors of society, while increasing revenue for treasuries 
to finance health systems and expand access to effective 
health care.
Such taxes should be combined with assessments of 
national health systems and actions to establish effective 
and efficient responses to the burden of diabetes to 
further expand fiscal space. Assessments should detail 
the burden of diabetes and its comorbidities, and their 
management at all levels of the health system, and 
involve analyses of the capability of human resources, 
the availability and costs (to individuals and health 
systems) of drugs and equipment, the functioning of 
supply-chain management, and how the services and 
platforms developed for communicable diseases can best 
be leveraged to also provide services for diabetes. In line 
with this recommendation, governments should 
prioritise data collection for the improvement of 
population health. Integrated digital health information 
systems are urgently needed to capture data about 
diabetes, its comorbidities, and their management in 
health systems, with timely analysis to inform planning 
and improve care.
Diabetes can be treated cost-effectively and its 
sequelae prevented if the disease is promptly diagnosed. 
The medicines required are on the WHO 2015 essential 
medicines list and are off-patent and affordable. 
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Additionally, angiotensin-converting enzyme inhibitors 
for protection against microvascular disease should be 
made widely available (indeed, enalapril is currently 
included in the WHO list of essential medicines, albeit 
as an antihypertensive).288 Unlike other essential 
medicines used for diabetes management, generic 
forms of insulin are generally not widely available. 
However, countries can purchase vials of human insulin 
at prices similar in cost per person each year to that paid 
for a 1 year supply of fixed-combination antiretroviral 
treatment. Given the absolute need for insulin treatment 
for type 1 diabetes, and the increasing need for insulin 
to treat type 2 diabetes, human insulin should be widely 
available for all those who need it. We believe that, in 
the context of LICs in sub-Saharan Africa, more 
expensive analogue insulins do not provide enough 
extra benefit to justify their current costs.149 Considering 
treatment, we urge countries to make available all 
necessary medicines for diabetes, hypertension, and 
cardiovascular disease on the WHO essential medicine 
list at no cost to all patients who need them. Although 
newer treatments for type 2 diabetes might have some 
benefit over standard oral antihyperglycaemic agents 
and insulin, these treatments could be considered a 
worthwhile investment for the public sector only once 
the countries have been able to provide essential 
services and medicines for diabetes (table 1).
Human resource shortage is a crucial challenge, and 
there is an urgent need to educate and train all groups 
of health professionals—ranging from community 
health workers to specialist physicians—in the 
management of diabetes at all stages of the care 
continuum to enable increased detection and improved 
treatment. The need for training is especially great in 
areas where there is already substantial contact with the 
health system—for example, in children so that 
diagnosis of type 1 diabetes is not missed, with fatal 
consequences; in areas of maternal health, to ensure 
diagnosis and treatment of gestational diabetes 
(panel 4); and in communicable diseases, to ensure 
effective management of interactions between diabetes 
and communicable diseases. Once recognised, 
diabetes—especially type 2 diabetes—can be effectively 
managed. It is generally more cost-effective to train 
existing staff to diagnose and treat diabetes than to 
invest in highly trained specialists. 
The sequelae of diabetes are insidious and present late 
in the disease course. Their effective management 
requires yearly monitoring at well equipped health 
centres with health-care professionals able to manage 
glycaemia and other cardiovascular risk factors and 
screen for complications to improve macrovascular and 
microvascular outcomes. It is essential that adequate 
referral pathways are in place to ensure regular 
monitoring and management of complications.
To minimise out-of-pocket costs from attending 
multiple clinics, services for diabetes, other cardiovascular 
risk factors, and chronic complications should be 
integrated wherever possible.
Overall, governments should work towards Target 3.8 
included in the SDGs: “achieve universal health coverage, 
including financial risk protection, access to quality 
essential health-care services and access to safe, effective, 
quality and affordable essential medicines and vaccines 
for all”.
Role of civil society
Civil society has a crucial role in catalysing change to 
improve access to health care and in holding governments 
to account. Advocacy from civil society was instrumental in 
the global movement for HIV, which prompted the 
convening of a special session of the UN General Assembly 
in 2001 and led to the first UN declaration focusing on a 
disease.289 Civil society could frame diabetes as an integral 
part of the global commitments to addressing NCDs and 
achieving universal health coverage, given links between 
diabetes and so many other risk factors and conditions, 
and use this narrative to build awareness and mobilise 
support among a broad range of stakeholders.
Effective deployment of civil society requires 
strengthening and expansion of networks and improved 
modes of communication. In many countries in sub-
Saharan Africa, diabetes organisations have an important 
role in educating the public, health-care providers, and 
governments about diabetes (see in-country case studies 
in appendices 2–8). We recommend that diabetes 
organisations should continue to promote the 
improvement in management of diabetes across sub-
Saharan Africa by tracking progress towards objectives set 
out in national NCD or diabetes plans, and by holding 
governments to account for their implementation. 
However, funding is needed to ensure sustained 
engagement of civil society. We urge donors and diabetes 
organisations in other world regions to consider funding 
or partnering with foundations in sub-Saharan Africa to 
enable mutual learning, strengthen the agenda for 
change, and ensure sustainability. Global NCD advocacy 
organisations—for example, the IDF, NCD Alliance, and 
World Heart Federation—have a key role in supporting 
local organisations in sub-Saharan Africa.
Although not known for certain, it is feared that many 
people with type 1 diabetes die undiagnosed or through 
lack of access to treatment. Civil society should be 
involved in raising awareness of type 1 diabetes and 
should ensure that government guarantee a supply of 
insulin to all patients, not just children.
Role of international donors
Although NCDs were identified as a priority in the 2011 
UN High-Level Commission,290 with renewed 
commitment in SDG 3, they still do not feature 
prominently on the agendas of most global health 
funders.14 To date, few donor agencies have provided 
assistance for NCDs or for diabetes specifically.
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We do not know whether obesity and diabetes have 
received so little attention because they are seen as 
problems of lifestyle rather than of health, or because 
infectious disease is seen as a greater menace. 
Alternatively, NCDs might be less easy for international 
donors to market to their supporters as worthy areas for 
investment. Yet, evidence strongly suggests that 
overweight, obesity, and diabetes are affected more by 
environment than individual factors.291 Investment in 
management of NCDs is imperative if the health gains 
achieved in many countries in sub-Saharan Africa during 
the Millennium Development Goal period (2000–15)—
because of improvements in maternal, neonatal, and 
child health, and communicable diseases in that region—
are to be sustained. Hence, donors should increasingly 
invest in evidence-based policies and health-systems-
wide strategies to address NCDs, communicable 
diseases, and maternal and child health.
Role of global agencies
As with international donors, global agencies have been 
slow to transition to a new world in which NCDs 
predominate. The 2011 UN High-Level Meeting on 
NCDs15,290 produced the UN General Assembly 
Resolution292 committing UN member states to the 
prevention and control of NCDs. In 2013, at the 
65th World Health Assembly, member states agreed to 
the aim of reducing premature mortality from NCDs by 
25% by the year 2025, relative to 2010 levels.293 However, 
in relation to action, apathy prevails;294 although a global 
coordination mechanism, a monitoring framework, an 
action plan, and a UN interagency task force have been 
established, their benefits to those living with NCDs is 
not sufficiently clear, given that targets are supposed to 
be met in 2025 (in only 8 years).
WHO needs to be engaged in the production of 
straightforward guidelines for countries looking to 
improve NCD prevention, diagnosis, and care. For 
example, lists of essential diagnostics for NCDs (akin to 
the WHO essential medicines list) could be very 
valuable.
WHO is well respected in sub-Saharan Africa and is 
well placed to have a leadership role. WHO also has the 
legitimacy to work with member states, other 
international agencies, and civil society organisations to 
mount an urgent and coordinated response to diabetes. 
However, this opportunity can only be realised if WHO 
acts on criticisms295 and lessons from the Ebola crisis to 
emerge as a leader in the battle against diabetes and 
NCDs. In addition to leading the response in countries, 
an under-resourced WHO should follow a collegial route, 
more widely involving external collaborators in efforts to 
support the diabetes response.24
The World Bank, with its development capability; the 
Global Fund, with its financing prowess; UNITAID, with 
expertise in innovative financing and creation of market 
dynamics to expand access to health technologies and 
medicines; Gavi, in effective partnerships to expand 
access to vaccines; the US Agency for International 
Development, in reproductive, maternal, and child 
health; and UNICEF, in building effective platforms for 
managing childrens’ problems, could work together to 
catalyse an integrated response to NCDs.
To date, most non-governmental organisations (NGOs) 
in international health have focused on maternal, 
neonatal, and child health; on communicable diseases; 
and on providing health care in conflict settings. 
Although some NGOs, such as the IDF’s Life for a Child 
programme and Santé Diabète, have focused on diabetes, 
these are exceptions. Encouragingly, Médecins Sans 
Frontières is increasing its involvement in NCDs.296
We encourage NGOs working in sub-Saharan Africa to 
recognise the importance of diabetes and obesity in the 
populations they care for and, when possible, work in 
concert with country health systems to find solutions to 
improve diabetes care. This recognition is particularly 
important for NGOs involved in communicable diseases 
and in improving maternal and neonatal health, wherein 
diabetes affects outcomes.
Research, development, and innovation
A global response to diabetes would not be possible 
without effective research and development and an 
innovation agenda to strengthen health systems, develop 
affordable technologies and medicines, and find 
innovative financing and service-delivery solutions.282,297 
Throughout this report, we have highlighted the scarcity 
of evidence needed to inform an appropriate broad-
based health system response to deal with diabetes, its 
complications, and other cardiovascular risk factors in 
sub-Saharan Africa. This deficit in knowledge is seen at 
all levels, from determining which measures to use to 
define diabetes, to defining the burden of disease, to 
making treatment decisions, and to planning cost-
effective health system development. Although some 
studies have been done in the region, those studies have 
often been small, out of date, or of poor quality. Our 
concern is that many of those studies have been 
assimilated into larger analyses and reports and thus 
will become instrumental in defining a response to 
diabetes in sub-Saharan Africa that might be wholly 
inappropriate to needs. There is a crucial need for high-
quality studies done in sub-Saharan Africa that are 
geared towards ensuring an effective health systems 
response. To date, funding of studies of diabetes and 
other NCDs in LMICs, including those in sub-Saharan 
Africa, has been woefully inadequate. However, given 
the urgency of the situation, we cannot advocate waiting 
to implement strategies for NCDs and diabetes until 
after the results of well done research studies have been 
reported. We do, however, strongly urge that all strategies 
are implemented in sub-Saharan Africa with 
implementation science methodology and are done on 
the background of a firm knowledge of baseline needs 
For more on the Life for a Child 
programme see http://www.idf.
org/lifeforachild
For Santé Diabète see  
http://www.santediabete.org/en
For more on Médecins Sans 
Frontières see http://www.msf.
org
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(including an accurate, population-level assessment of 
disease burden). We also believe that no programme of 
health care will truly maximise its potential unless there 
is local ownership—this necessitates co-development of 
research and implementation programmes with local 
users and providers.298
The shortage of health professionals is a major barrier to 
expansion of services in sub-Saharan Africa. Given 
resource constraints, rapid expansion in numbers of 
health professionals in the near future is not realistic. 
Hence, addressing human resource shortages will require 
a combination of strategies. The first of these strategies is 
task-shifting or task-sharing, which has been effectively 
implemented in sub-Saharan Africa to engage a broader 
group of health professionals in diabetes care (see earlier 
section on service delivery models for diabetes). The 
second strategy is to leverage novel technology advances in 
communications, including distance learning and 
e-learning, through use of online courses to improve the 
knowledge and competence of the existing health 
workforce.299 The third strategy, among others, is to use 
mobile technologies and SMS text messaging to improve 
management of communications and processes in health 
systems—for example, in communicating results,274 
attending clinic appointments,276 and scaling up public 
health and prevention interventions.273 In addition to 
freeing up health-care-worker time, these measures also 
improve patient self-management of long-term illnesses.300
Innovative opportunities also exist for increasing 
financing resources. Financing initiatives such as the 
airline solidarity levy and Debt2Health, which have been 
used successfully for AIDS, tuberculosis, malaria, and 
children’s immunisation programmes, offer possibilities 
for funding of health systems and diabetes care,301,302 as 
well as research.303
Conclusion
With rapid socioeconomic transitions occurring in sub-
Saharan Africa, there is a risk that the increasing 
prevalence of diabetes (and associated NCDs) will 
overwhelm already struggling health services and have 
adverse consequences for individuals and economies. 
This Commission therefore chose to focus on this region 
as a priority, although our findings could be translated to 
other world regions facing similar challenges.
Our methods consisted of extensive reviews of the 
literature; soliciting of expert opinion; performance of 
primary research studies; and convening of 
Commissioners’ meetings to discuss findings, 
challenges, and solutions. The major limitation that 
runs throughout all elements of the Commission is the 
scarcity of reliable data to inform findings. However, the 
findings presented here are robust to the current state of 
knowledge in the region, and this Commission should 
therefore serve as important reading for all members of 
the health-care community (from health-care workers, to 
ministers of health, and to heads of global development 
agencies) whose aim is to improve care for people with 
diabetes in sub-Saharan Africa. The finding of a paucity 
of reliable data is also a key message of the Commission, 
and more needs to be done to address the dearth of data 
in the region.
We conclude that sub-Saharan Africa is not prepared 
for the increasing burden of diabetes brought about by 
rapid and ongoing transitions. Effective management of 
diabetes in sub-Saharan Africa will require careful 
considerations about the expansion of services to meet 
current and future burden, while ensuring that services 
are integrated with those for other chronic diseases. The 
health, economic, and societal consequences of inaction 
will be huge. Decisive action is needed now, by all 
stakeholders, to address the scale and urgency of diabetes 
in sub-Saharan Africa.
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